20-quarter listed-company comparison

Drug Manufacturers - Specialty & Generic Stocks

Drug Manufacturers - Specialty & Generic: Teva Pharmaceutical Industries Limited owns the largest revenue base; Liquidia Corporation has the fastest current growth.

The industry itself · before any single company

How has Drug Manufacturers - Specialty & Generic moved against S&P 500?

The line below covers 5.2 years. Over the most recent two of them this industry is 45% ahead of S&P 500. Earnings across its companies fell 9% on average over the last four reported quarters.

FADING · −2 in 4w~Price up, without the fundamentals confirming17 of 49 companies ahead of S&P 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more

RS — · 25/49 >200d (−4) · 17/49 lead (−2) · EPS 30/49↑

Drug Manufacturers - Specialty & Generic, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Strength anatomy MixedHow much of the industry is participating, how recently, and whether the movers score well.

Together17 of 49 stocks moving

Fresh3 crossed in the last 4 weeks

Backed by scoresmovers score +8 vs the industry average

Down the cap ladder — bar is now, tick is four weeks ago

Large 4/10+1

Mid 7/17−2

Small 6/22−1

Participation is not spreading downward this month; the larger companies are still carrying most of it.

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 49 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

Sector relative strength · before individual stocks

Is Drug Manufacturers - Specialty & Generic outperforming S&P 500?

Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 27.8% over the last 52 weeks. Over 13 weeks the gap is a lead of 2.8%. 16 of 28 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. Liquidia Corporation is the strongest against the sector itself at +84.9%.

+2.8%Sector vs S&P 500 · 13 weeks

+27.8%Sector vs S&P 500 · 52 weeks

16/28Stocks leading S&P 500

11/28Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 27.8% over 52 weeks and 2.8% over 13 weeks. 16 of 28 covered companies beat the S&P 500 on Mansfield relative strength, while 11 of 28 beat the sector itself. Liquidia Corporation has the fastest current revenue growth at 100%, across 24 of 28 comparable companies.

Is the Drug Manufacturers - Specialty & Generic sector outperforming S&P 500?

Which Drug Manufacturers - Specialty & Generic company is largest by revenue?

Teva Pharmaceutical Industries Limited leads with revenue of $17,349 million, based on 24 of 28 comparable companies through Mar 2026.

Which Drug Manufacturers - Specialty & Generic company is growing fastest?

Liquidia Corporation has the fastest current revenue growth at 100%, across 24 of 28 comparable companies.

Which Drug Manufacturers - Specialty & Generic company has the strongest 4-Factor Sector Score?

Neurocrine Biosciences, Inc. ranks first at 76/100 with 82% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Drug Manufacturers - Specialty & Generic company reports the most CAPEX?

Teva Pharmaceutical Industries Limited reports the largest latest CAPEX at $168 million, with 28 of 28 companies comparable.

Which Drug Manufacturers - Specialty & Generic company has the least gross debt?

United Therapeutics Corporation has the lowest comparable gross debt at $0 million. Bausch Health Companies Inc. has the highest at $20,795 million.

Which Drug Manufacturers - Specialty & Generic company has the lowest comparable PEG?

Alkermes plc has the lowest comparable Guarded PEG at 0.58, among 7 of 28 companies that pass the metric’s comparability rules.

How much history does this Drug Manufacturers - Specialty & Generic comparison include?

The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Companies

complete canonical membership

Combined market value

$261.9B

Haleon plc

Revenue growing

20/24

positive TTM year-on-year growth

Beating S&P 500

16/28

positive Mansfield relative strength

Global company selection

00 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

Neurocrine Biosciences, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 82% evidence confidence.

Lantheus Holdings, Inc. looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.

Lantheus Holdings, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.

1. Neurocrine Biosciences, Inc. · NBIX

76.0/100 · Favorable setup · 82% evidence

Exact sum: 28.7 + 16.4 + 14.6 + 16.3 = 76

Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

28.7/35Growth & earnings

Revenue 28.6% · PAT 100% · OPM change 19.6 pp

83% evidence

16.4/25Capital efficiency

ROCE 5.3% · debt/equity 0.12×

80% evidence

14.6/20Valuation

P/E 20.3× · PEG 0.73

65% evidence

16.3/20Relative strength

RS sector 8% · RS bench 17.9% · 1Y 41.8%

100% evidence

2. Liquidia Corporation · LQDA

69.6/100 · Favorable setup · 65% evidence

Exact sum: 25.7 + 15.3 + 8.6 + 20 = 69.6

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

25.7/35Growth & earnings

Revenue 100% · PAT — · OPM change 1181.7 pp

62% evidence

15.3/25Capital efficiency

ROCE 29.4% · debt/equity 1.7×

80% evidence

8.6/20Valuation

P/E 269.6× · PEG —

15% evidence

20.0/20Relative strength

RS sector 84.9% · RS bench 98.8% · 1Y 391.1%

100% evidence

3. Indivior Pharmaceuticals, Inc. · INDV

69.1/100 · Favorable setup · 65% evidence

Exact sum: 24.1 + 21.6 + 11.4 + 12 = 69.1

Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

24.1/35Growth & earnings

Revenue 10.3% · PAT — · OPM change 18.4 pp

62% evidence

21.6/25Capital efficiency

ROCE 34.8% · debt/equity 0×

80% evidence

11.4/20Valuation

P/E 3.1× · PEG —

15% evidence

12.0/20Relative strength

RS sector 9.1% · RS bench 18.4% · 1Y 94.7%

100% evidence

4. Kiniksa Pharmaceuticals International, plc · KNSA

65.6/100 · Favorable setup · 65% evidence

Exact sum: 22.9 + 14.6 + 9.3 + 18.8 = 65.6

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

22.9/35Growth & earnings

Revenue 56.4% · PAT — · OPM change 4.1 pp

62% evidence

14.6/25Capital efficiency

ROCE 5% · debt/equity 0.01×

80% evidence

9.3/20Valuation

P/E 53.5× · PEG —

15% evidence

18.8/20Relative strength

RS sector 50.3% · RS bench 62.9% · 1Y 148.4%

100% evidence

5. Eton Pharmaceuticals, Inc. · ETON

63.8/100 · Mixed-positive evidence · 65% evidence

Exact sum: 24.7 + 10.6 + 9 + 19.5 = 63.8

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

24.7/35Growth & earnings

Revenue 79.2% · PAT — · OPM change 12.6 pp

62% evidence

10.6/25Capital efficiency

ROCE 4.3% · debt/equity 1×

80% evidence

9.0/20Valuation

P/E 93.8× · PEG —

15% evidence

19.5/20Relative strength

RS sector 79.2% · RS bench 93.6% · 1Y 230.2%

100% evidence

6. Amneal Pharmaceuticals, Inc. · AMRX

60.6/100 · Mixed-positive evidence · 72% evidence

Exact sum: 22.9 + 10.4 + 9.5 + 17.8 = 60.6

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

22.9/35Growth & earnings

Revenue 7.7% · PAT 100% · OPM change 5.2 pp

83% evidence

10.4/25Capital efficiency

ROCE 5.6% · debt/equity 67.4×

80% evidence

9.5/20Valuation

P/E 32.7× · PEG —

15% evidence

17.8/20Relative strength

RS sector 26.9% · RS bench 37.5% · 1Y 139.6%

100% evidence

7. Lantheus Holdings, Inc. · LNTH

57.4/100 · Mixed-positive evidence · 82% evidence

Exact sum: 12.1 + 14.7 + 13.5 + 17.1 = 57.4

Decision use: Price leads the evidence: RS versus the benchmark is 30%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

12.1/35Growth & earnings

Revenue 0.6% · PAT 9.8% · OPM change -5.8 pp

83% evidence

14.7/25Capital efficiency

ROCE 4.3% · debt/equity 0.47×

80% evidence

13.5/20Valuation

P/E 18.3× · PEG 1.02

65% evidence

17.1/20Relative strength

RS sector 20.3% · RS bench 30% · 1Y 45.4%

100% evidence

8. Viatris Inc. · VTRS

55.3/100 · Mixed-positive evidence · 65% evidence

Exact sum: 21.5 + 9.3 + 8.7 + 15.8 = 55.3

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

21.5/35Growth & earnings

Revenue 1.6% · PAT — · OPM change 86.3 pp

62% evidence

9.3/25Capital efficiency

ROCE -0.3% · debt/equity 0.98×

80% evidence

8.7/20Valuation

P/E 216.6× · PEG —

15% evidence

15.8/20Relative strength

RS sector 16.9% · RS bench 26.6% · 1Y 102.7%

100% evidence

9. Haleon plc · HLN

54.1/100 · Mixed-positive evidence · 67% evidence

Exact sum: 19 + 13.8 + 12.4 + 8.9 = 54.1

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

19.0/35Growth & earnings

Revenue -1.8% · PAT 14% · OPM change 9.1 pp

53% evidence

13.8/25Capital efficiency

ROCE 2.2% · debt/equity 0.52×

60% evidence

12.4/20Valuation

P/E 20.1× · PEG 1.04

65% evidence

8.9/20Relative strength

RS sector -10.2% · RS bench -2% · 1Y 6.3%

100% evidence

10. Alkermes plc · ALKS

51.0/100 · Mixed-positive evidence · 82% evidence

Exact sum: 8.9 + 9 + 14.4 + 18.7 = 51

Decision use: Price leads the evidence: RS versus the benchmark is 37.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

8.9/35Growth & earnings

Revenue 3.2% · PAT -57% · OPM change -16.8 pp

83% evidence

9.0/25Capital efficiency

ROCE -1.8% · debt/equity 0.9×

80% evidence

14.4/20Valuation

P/E 39.3× · PEG 0.58

65% evidence

18.7/20Relative strength

RS sector 27.2% · RS bench 37.9% · 1Y 90.2%

100% evidence

11. Xeris Biopharma Holdings, Inc. · XERS

50.9/100 · Thin evidence · provisional · 59% evidence

Exact sum: 24 + 7.1 + 8.9 + 10.9 = 50.9

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

24.0/35Growth & earnings

Revenue 41.9% · PAT — · OPM change 14.6 pp

62% evidence

7.1/25Capital efficiency

ROCE 3.2% · debt/equity 19.92×

80% evidence

8.9/20Valuation

P/E 96.7× · PEG —

15% evidence

10.9/20Relative strength

RS sector -2.7% · RS bench 6.6% · 1Y 53.2%

70% evidence

12. Phibro Animal Health Corporation · PAHC

50.3/100 · Mixed-positive evidence · 76% evidence

Exact sum: 23.8 + 10.9 + 10.2 + 5.4 = 50.3

Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -24.6% and the one-year return is 39.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.

23.8/35Growth & earnings

Revenue 26.1% · PAT 100% · OPM change 2 pp

83% evidence

10.9/25Capital efficiency

ROCE 4% · debt/equity 2.03×

80% evidence

10.2/20Valuation

P/E 23.7× · PEG 1.31

65% evidence

5.4/20Relative strength

RS sector -24.6% · RS bench -18% · 1Y 39.3%

70% evidence

13. ANI Pharmaceuticals, Inc. · ANIP

48.6/100 · Mixed-negative evidence · 65% evidence

Exact sum: 21.3 + 11.3 + 10.6 + 5.4 = 48.6

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

21.3/35Growth & earnings

Revenue 36.9% · PAT — · OPM change 3.1 pp

62% evidence

11.3/25Capital efficiency

ROCE 3.4% · debt/equity 1.09×

80% evidence

10.6/20Valuation

P/E 19.5× · PEG —

15% evidence

5.4/20Relative strength

RS sector -17.1% · RS bench -9.3% · 1Y 26.8%

100% evidence

14. Trulieve Cannabis Corp. · TRLV

45.7/100 · Mixed-negative evidence · 65% evidence

Exact sum: 15.8 + 12.8 + 11.5 + 5.6 = 45.7

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

15.8/35Growth & earnings

Revenue -1.4% · PAT — · OPM change 0.6 pp

62% evidence

12.8/25Capital efficiency

ROCE 5.6% · debt/equity 0.55×

80% evidence

11.5/20Valuation

P/E -13.3× · PEG —

15% evidence

5.6/20Relative strength

RS sector -7.1% · RS bench 1.3% · 1Y 77.2%

100% evidence

15. Supernus Pharmaceuticals, Inc. · SUPN

45.2/100 · Mixed-negative evidence · 65% evidence

Exact sum: 19.5 + 11.4 + 9.6 + 4.7 = 45.2

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

19.5/35Growth & earnings

Revenue 16.3% · PAT -147.5% · OPM change 2.8 pp

62% evidence

11.4/25Capital efficiency

ROCE -0.8% · debt/equity 0.03×

80% evidence

9.6/20Valuation

P/E 27.4× · PEG —

15% evidence

4.7/20Relative strength

RS sector -15.7% · RS bench -8.1% · 1Y 34.4%

100% evidence

16. Teva Pharmaceutical Industries Limited · TEVA

45.0/100 · Mixed-negative evidence · 65% evidence

Exact sum: 18 + 9.8 + 9.9 + 7.3 = 45

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

18.0/35Growth & earnings

Revenue 4.4% · PAT — · OPM change 4.2 pp

62% evidence

9.8/25Capital efficiency

ROCE 2.4% · debt/equity 2.05×

80% evidence

9.9/20Valuation

P/E 22.6× · PEG —

15% evidence

7.3/20Relative strength

RS sector -3.3% · RS bench 4.7% · 1Y 105.9%

100% evidence

17. Elanco Animal Health Incorporated · ELAN

44.0/100 · Mixed-negative evidence · 72% evidence

Exact sum: 14.1 + 10.2 + 8.5 + 11.2 = 44

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

14.1/35Growth & earnings

Revenue 10.5% · PAT -164.9% · OPM change 2.1 pp

83% evidence

10.2/25Capital efficiency

ROCE 1.2% · debt/equity 0.61×

80% evidence

8.5/20Valuation

P/E 335.7× · PEG —

15% evidence

11.2/20Relative strength

RS sector -2.7% · RS bench 5.8% · 1Y 85.1%

100% evidence

18. United Therapeutics Corporation · UTHR

42.8/100 · Mixed-negative evidence · 82% evidence

Exact sum: 13.8 + 17.9 + 5.6 + 5.5 = 42.8

Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.

13.8/35Growth & earnings

Revenue 5.9% · PAT 6.5% · OPM change -6.5 pp

83% evidence

17.9/25Capital efficiency

ROCE 5% · debt/equity 0×

80% evidence

5.6/20Valuation

P/E 21.9× · PEG 2.7

65% evidence

5.5/20Relative strength

RS sector -7.4% · RS bench 0.5% · 1Y 77.9%

100% evidence

19. Prestige Consumer Healthcare Inc. · PBH

42.0/100 · Mixed-negative evidence · 72% evidence

Exact sum: 10.8 + 13.9 + 11 + 6.3 = 42

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

10.8/35Growth & earnings

Revenue -4.3% · PAT -11.2% · OPM change -3 pp

83% evidence

13.9/25Capital efficiency

ROCE 2.3% · debt/equity 0.55×

80% evidence

11.0/20Valuation

P/E 15.2× · PEG —

15% evidence

6.3/20Relative strength

RS sector -26% · RS bench -19% · 1Y -29.8%

100% evidence

20. Zoetis Inc. · ZTS

37.1/100 · Mixed-negative evidence · 82% evidence

Exact sum: 13.8 + 13.7 + 8.2 + 1.4 = 37.1

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

13.8/35Growth & earnings

Revenue 2.6% · PAT 5.8% · OPM change -1.5 pp

83% evidence

13.7/25Capital efficiency

ROCE 6.7% · debt/equity 2.86×

80% evidence

8.2/20Valuation

P/E 19.6× · PEG 2.03

65% evidence

1.4/20Relative strength

RS sector -44.7% · RS bench -39.2% · 1Y -47.4%

100% evidence

21. Harrow, Inc. · HROW

33.2/100 · Thin evidence · provisional · 56% evidence

Exact sum: 13.3 + 4.2 + 10 + 5.7 = 33.2

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

13.3/35Growth & earnings

Revenue 26.3% · PAT — · OPM change -26.5 pp

62% evidence

4.2/25Capital efficiency

ROCE -8.7% · debt/equity 10.75×

80% evidence

10.0/20Valuation

P/E — · PEG —

0% evidence

5.7/20Relative strength

RS sector -18.1% · RS bench -10.6% · 1Y 25.9%

70% evidence

22. Hims & Hers Health, Inc. · HIMS

31.3/100 · Adverse evidence · 72% evidence

Exact sum: 10.2 + 5.3 + 9.1 + 6.7 = 31.3

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

10.2/35Growth & earnings

Revenue 32.8% · PAT -107.3% · OPM change -22.8 pp

83% evidence

5.3/25Capital efficiency

ROCE -6.9% · debt/equity 2.54×

80% evidence

9.1/20Valuation

P/E 63.7× · PEG —

15% evidence

6.7/20Relative strength

RS sector -28.1% · RS bench -20.4% · 1Y -53.1%

100% evidence

23. Bausch Health Companies Inc. · BHC

28.3/100 · Adverse evidence · 65% evidence

Exact sum: 10.7 + 4.8 + 10.9 + 1.9 = 28.3

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

10.7/35Growth & earnings

Revenue 8.8% · PAT — · OPM change -49.8 pp

62% evidence

4.8/25Capital efficiency

ROCE -4.5% · debt/equity 55.31×

80% evidence

10.9/20Valuation

P/E 16.5× · PEG —

15% evidence

1.9/20Relative strength

RS sector -36.7% · RS bench -30.5% · 1Y -20.8%

100% evidence

24. Perrigo Company plc · PRGO

27.9/100 · Thin evidence · provisional · 56% evidence

Exact sum: 8.2 + 6 + 10 + 3.7 = 27.9

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

8.2/35Growth & earnings

Revenue -3.6% · PAT — · OPM change -42.9 pp

62% evidence

6.0/25Capital efficiency

ROCE -4.8% · debt/equity 1.45×

80% evidence

10.0/20Valuation

P/E — · PEG —

0% evidence

3.7/20Relative strength

RS sector -41.4% · RS bench -35.2% · 1Y -61.3%

70% evidence

25. Amylyx Pharmaceuticals, Inc. · AMLX

52.8/100 · Thin evidence · provisional · 45% evidence

Exact sum: 17.3 + 10 + 10.1 + 15.4 = 52.8

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

17.3/35Growth & earnings

Revenue — · PAT — · OPM change 6111.6 pp

13% evidence

10.0/25Capital efficiency

ROCE -18.3% · debt/equity 0.02×

68% evidence

10.1/20Valuation

P/E 21× · PEG —

15% evidence

15.4/20Relative strength

RS sector 19.6% · RS bench 29.7% · 1Y 153.6%

100% evidence

26. BioCryst Pharmaceuticals, Inc. · BCRX

42.9/100 · Thin evidence · provisional · 49% evidence

Exact sum: 12 + 5.6 + 11.1 + 14.2 = 42.9

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

12.0/35Growth & earnings

Revenue — · PAT — · OPM change -463.2 pp

32% evidence

5.6/25Capital efficiency

ROCE -230.1% · debt/equity —

57% evidence

11.1/20Valuation

P/E 6.4× · PEG —

15% evidence

14.2/20Relative strength

RS sector 2.2% · RS bench 11.2% · 1Y 22.5%

100% evidence

27. HUTCHMED (China) Limited · HCM

41.1/100 · Thin evidence · provisional · 35% evidence

Exact sum: 16.9 + 9.9 + 11.3 + 3 = 41.1

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

16.9/35Growth & earnings

Revenue — · PAT — · OPM change —

9% evidence

9.9/25Capital efficiency

ROCE -1.5% · debt/equity —

34% evidence

11.3/20Valuation

P/E 5.1× · PEG —

15% evidence

3.0/20Relative strength

RS sector -32.5% · RS bench -26.1% · 1Y -35.1%

100% evidence

28. Regencell Bioscience Holdings Limited · RGC

31.8/100 · Thin evidence · provisional · 37% evidence

Exact sum: 13.4 + 8.4 + 10 + 0 = 31.8

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

13.4/35Growth & earnings

Revenue — · PAT — · OPM change —

24% evidence

8.4/25Capital efficiency

ROCE -60.5% · debt/equity —

34% evidence

10.0/20Valuation

P/E — · PEG —

0% evidence

0.0/20Relative strength

RS sector -74% · RS bench -71.8% · 1Y -54%

100% evidence

01 · compare level, then change

Revenue Scale & Growth Durability

Teva Pharmaceutical Industries Limited has the highest Revenue among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $17,349 million. Viatris Inc. is next at $14,563 million. Liquidia Corporation has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Teva Pharmaceutical Industries Limited is the scale leader at $17,349 million, 19.1% ahead of Viatris Inc.. Liquidia Corporation's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 1957.1% from a $288 million base, with 19 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderTeva Pharmaceutical Industries Limited · $17,349 million

Gap19.1% versus #2 · Viatris Inc.

Persistence7/8 recent comparable periods

Coverage24/28 companies · 488 observations

Investor read: Teva Pharmaceutical Industries Limited is the scale benchmark; Liquidia Corporation is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Teva Pharmaceutical Industries Limited's growth falls below Liquidia Corporation's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1Teva Pharmaceutical Industries Limited TEVA$17.3B

2Viatris Inc. VTRS$14.6B

3Bausch Health Companies Inc. BHC$11.9B

4Haleon plc HLN · older report$11.0B

5Zoetis Inc. ZTS$9.5B

Revenue growthfastest growers

1Liquidia Corporation LQDA100%

2Eton Pharmaceuticals, Inc. ETON79%

3Kiniksa Pharmaceuticals International, plc KNSA56%

4Xeris Biopharma Holdings, Inc. XERS42%

5ANI Pharmaceuticals, Inc. ANIP37%

Revenue · company comparison

24/28 level · 24/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
Teva Pharmaceutical Industries Limited TEVA	$4.0B	2.3%	Mar 2026
Viatris Inc. VTRS	$3.5B	8.1%	Mar 2026
Haleon plc HLN	$2.8B	0.6%	Dec 2025
Bausch Health Companies Inc. BHC	$2.5B	12%	Mar 2026
Zoetis Inc. ZTS	$2.3B	2.9%	Mar 2026
Elanco Animal Health Incorporated ELAN	$1.4B	15%	Mar 2026
Perrigo Company plc PRGO	$969M	-7.2%	Mar 2026
Neurocrine Biosciences, Inc. NBIX	$815M	42%	Mar 2026
United Therapeutics Corporation UTHR	$782M	-1.5%	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	$723M	4.0%	Mar 2026
Hims & Hers Health, Inc. HIMS	$608M	3.8%	Mar 2026
Alkermes plc ALKS	$393M	28%	Mar 2026
Phibro Animal Health Corporation PAHC	$384M	10%	Mar 2026
Lantheus Holdings, Inc. LNTH	$377M	1.1%	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	$317M	19%	Mar 2026
Trulieve Cannabis Corp. TRLV	$287M	-3.7%	Mar 2026
Prestige Consumer Healthcare Inc. PBH	$282M	-5.1%	Mar 2026
HUTCHMED (China) Limited HCM	$271M	-17%	Dec 2025
ANI Pharmaceuticals, Inc. ANIP	$237M	20%	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	$214M	55%	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	$208M	39%	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	$156M	6.9%	Mar 2026
Liquidia Corporation LQDA	$133M	4,333%	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	$83M	38%	Mar 2026
Harrow, Inc. HROW	$44M	-8.3%	Mar 2026
Eton Pharmaceuticals, Inc. ETON	$24M	41%	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	$-1M	-101%	Mar 2026

Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021$294M

Dec 2021$324M

Mar 2022$279M

Jun 2022$276M

Sep 2022$252M

Dec 2022$305M

Mar 2023$288M

Jun 2023$617M

Sep 2023$381M

Dec 2023$377M

Mar 2024$350M

Jun 2024$399M

Sep 2024$378M

Dec 2024$430M

Mar 2025$307M

Jun 2025$391M

Sep 2025$394M

Dec 2025$385M

Mar 2026$393M

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021$1.1B

Dec 2021$1.1B

Mar 2022$1.2B

Jun 2022$1.2B

Sep 2022$1.0B

Dec 2022$985M

Mar 2023$1.3B

Jun 2023$1.1B

Sep 2023$1.1B

Dec 2023$1.0B

Mar 2024$1.2B

Jun 2024$1.2B

Sep 2024$1.0B

Dec 2024$1.0B

Mar 2025$1.2B

Jun 2025$1.2B

Sep 2025$1.1B

Dec 2025$1.1B

Mar 2026$1.4B

Jun 2026—

Haleon plc · HLN

Sep 2021$2.5B

Dec 2021$2.5B

Mar 2022$2.6B

Jun 2022$2.6B

Sep 2022$2.9B

Dec 2022$2.8B

Mar 2023$3.0B

Jun 2023$2.8B

Sep 2023$2.8B

Dec 2023$2.8B

Mar 2024$2.9B

Jun 2024$2.8B

Sep 2024$2.8B

Dec 2024$2.8B

Mar 2025$2.7B

Jun 2025$2.7B

Sep 2025$2.8B

Dec 2025$2.8B

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021$74M

Dec 2021$85M

Mar 2022$101M

Jun 2022$114M

Sep 2022$145M

Dec 2022$167M

Mar 2023$191M

Jun 2023$208M

Sep 2023$227M

Dec 2023$247M

Mar 2024$278M

Jun 2024$316M

Sep 2024$402M

Dec 2024$481M

Mar 2025$586M

Jun 2025$545M

Sep 2025$599M

Dec 2025$618M

Mar 2026$608M

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021$12M

Dec 2021$19M

Mar 2022$32M

Jun 2022$27M

Sep 2022$99M

Dec 2022$62M

Mar 2023$48M

Jun 2023$71M

Sep 2023$67M

Dec 2023$83M

Mar 2024$80M

Jun 2024$109M

Sep 2024$112M

Dec 2024$123M

Mar 2025$138M

Jun 2025$157M

Sep 2025$181M

Dec 2025$202M

Mar 2026$214M

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021$102M

Dec 2021$130M

Mar 2022$209M

Jun 2022$224M

Sep 2022$239M

Dec 2022$263M

Mar 2023$301M

Jun 2023$322M

Sep 2023$320M

Dec 2023$354M

Mar 2024$370M

Jun 2024$394M

Sep 2024$379M

Dec 2024$391M

Mar 2025$373M

Jun 2025$378M

Sep 2025$384M

Dec 2025$407M

Mar 2026$377M

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021$3M

Dec 2021$3M

Mar 2022$3M

Jun 2022$4M

Sep 2022$3M

Dec 2022$5M

Mar 2023$4M

Jun 2023$5M

Sep 2023$4M

Dec 2023$5M

Mar 2024$3M

Jun 2024$4M

Sep 2024$4M

Dec 2024$3M

Mar 2025$3M

Jun 2025$9M

Sep 2025$54M

Dec 2025$92M

Mar 2026$133M

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021$296M

Dec 2021$312M

Mar 2022$311M

Jun 2022$378M

Sep 2022$388M

Dec 2022$412M

Mar 2023$420M

Jun 2023$453M

Sep 2023$499M

Dec 2023$515M

Mar 2024$515M

Jun 2024$590M

Sep 2024$622M

Dec 2024$628M

Mar 2025$573M

Jun 2025$688M

Sep 2025$795M

Dec 2025$806M

Mar 2026$815M

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021$3.9B

Dec 2021$4.1B

Mar 2022$3.7B

Jun 2022$3.8B

Sep 2022$3.6B

Dec 2022$3.9B

Mar 2023$3.7B

Jun 2023$3.9B

Sep 2023$3.9B

Dec 2023$4.5B

Mar 2024$3.8B

Jun 2024$4.2B

Sep 2024$4.3B

Dec 2024$4.2B

Mar 2025$3.9B

Jun 2025$4.2B

Sep 2025$4.5B

Dec 2025$4.7B

Mar 2026$4.0B

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021$445M

Dec 2021$415M

Mar 2022$462M

Jun 2022$467M

Sep 2022$516M

Dec 2022$492M

Mar 2023$507M

Jun 2023$597M

Sep 2023$609M

Dec 2023$615M

Mar 2024$678M

Jun 2024$715M

Sep 2024$749M

Dec 2024$736M

Mar 2025$794M

Jun 2025$799M

Sep 2025$800M

Dec 2025$790M

Mar 2026$782M

Jun 2026—

Viatris Inc. · VTRS

Sep 2021$4.5B

Dec 2021$4.3B

Mar 2022$4.2B

Jun 2022$4.1B

Sep 2022$4.1B

Dec 2022$3.9B

Mar 2023$3.7B

Jun 2023$3.9B

Sep 2023$3.9B

Dec 2023$3.8B

Mar 2024$3.7B

Jun 2024$3.8B

Sep 2024$3.8B

Dec 2024$3.5B

Mar 2025$3.3B

Jun 2025$3.6B

Sep 2025$3.8B

Dec 2025$3.7B

Mar 2026$3.5B

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021$2.0B

Dec 2021$2.0B

Mar 2022$2.0B

Jun 2022$2.1B

Sep 2022$2.0B

Dec 2022$2.0B

Mar 2023$2.0B

Jun 2023$2.2B

Sep 2023$2.2B

Dec 2023$2.2B

Mar 2024$2.2B

Jun 2024$2.4B

Sep 2024$2.4B

Dec 2024$2.3B

Mar 2025$2.2B

Jun 2025$2.5B

Sep 2025$2.4B

Dec 2025$2.4B

Mar 2026$2.3B

Jun 2026—

Revenue growth · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-9.2%

Sep 2022-14%

Dec 2022-5.9%

Mar 20233.2%

Jun 2023124%

Sep 202351%

Dec 202324%

Mar 202422%

Jun 2024-35%

Sep 2024-0.8%

Dec 202414%

Mar 2025-12%

Jun 2025-2.0%

Sep 20254.2%

Dec 2025-10%

Mar 202628%

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-8.1%

Sep 2022-9.3%

Dec 2022-11%

Mar 20232.5%

Jun 2023-10%

Sep 20234.1%

Dec 20235.1%

Mar 2024-4.1%

Jun 202412%

Sep 2024-3.6%

Dec 2024-1.5%

Mar 2025-1.0%

Jun 20254.8%

Sep 202510%

Dec 202512%

Mar 202615%

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 202214%

Jun 202213%

Sep 202216%

Dec 202212%

Mar 202314%

Jun 20237.5%

Sep 2023-3.3%

Dec 2023-0.4%

Mar 2024-2.2%

Jun 20240.8%

Sep 2024-0.6%

Dec 2024-0.3%

Mar 2025-6.1%

Jun 2025-1.3%

Sep 2025-0.2%

Dec 20250.6%

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202287%

Sep 202296%

Dec 202296%

Mar 202389%

Jun 202382%

Sep 202357%

Dec 202348%

Mar 202446%

Jun 202452%

Sep 202477%

Dec 202495%

Mar 2025111%

Jun 202572%

Sep 202549%

Dec 202528%

Mar 20263.8%

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022238%

Sep 2022725%

Dec 2022226%

Mar 202350%

Jun 2023163%

Sep 2023-32%

Dec 202334%

Mar 202467%

Jun 202454%

Sep 202467%

Dec 202448%

Mar 202573%

Jun 202544%

Sep 202562%

Dec 202564%

Mar 202655%

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022122%

Sep 2022134%

Dec 2022102%

Mar 202344%

Jun 202344%

Sep 202334%

Dec 202335%

Mar 202423%

Jun 202422%

Sep 202418%

Dec 202410%

Mar 20250.8%

Jun 2025-4.1%

Sep 20251.3%

Dec 20254.1%

Mar 20261.1%

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202233%

Sep 20220.0%

Dec 202267%

Mar 202333%

Jun 202325%

Sep 202333%

Dec 20230.0%

Mar 2024-25%

Jun 2024-20%

Sep 20240.0%

Dec 2024-40%

Mar 20250.0%

Jun 2025125%

Sep 20251,250%

Dec 20252,967%

Mar 20264,333%

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202231%

Sep 202231%

Dec 202232%

Mar 202335%

Jun 202320%

Sep 202329%

Dec 202325%

Mar 202423%

Jun 202430%

Sep 202425%

Dec 202422%

Mar 202511%

Jun 202517%

Sep 202528%

Dec 202528%

Mar 202642%

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-3.2%

Sep 2022-7.5%

Dec 2022-5.3%

Mar 20230.0%

Jun 20232.4%

Sep 20237.1%

Dec 202315%

Mar 20244.3%

Jun 20247.4%

Sep 202413%

Dec 2024-5.1%

Mar 20251.9%

Jun 20250.3%

Sep 20253.4%

Dec 202511%

Mar 20262.3%

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20224.5%

Sep 202216%

Dec 202219%

Mar 20239.7%

Jun 202328%

Sep 202318%

Dec 202325%

Mar 202434%

Jun 202420%

Sep 202423%

Dec 202420%

Mar 202517%

Jun 202512%

Sep 20256.8%

Dec 20257.3%

Mar 2026-1.5%

Jun 2026—

Viatris Inc. · VTRS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-10%

Sep 2022-10%

Dec 2022-11%

Mar 2023-11%

Jun 2023-4.8%

Sep 2023-3.3%

Dec 2023-1.0%

Mar 2024-1.8%

Jun 2024-3.1%

Sep 2024-4.9%

Dec 2024-8.1%

Mar 2025-11%

Jun 2025-5.7%

Sep 20250.2%

Dec 20255.0%

Mar 20268.1%

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20225.3%

Sep 20220.6%

Dec 20223.7%

Mar 20230.7%

Jun 20236.2%

Sep 20237.4%

Dec 20238.5%

Mar 20249.5%

Jun 20248.3%

Sep 202411%

Dec 20244.7%

Mar 20250.4%

Jun 20254.2%

Sep 20250.5%

Dec 20253.0%

Mar 20262.9%

Jun 2026—

02 · compare level, then change

Operating Economics & Margin Trend

Liquidia Corporation has the highest OPM among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 46.3%. Indivior Pharmaceuticals, Inc. is next at 43.2%. Amylyx Pharmaceuticals, Inc. has the highest Margin change at +6111.6 percentage points, so level and change sit with different companies. 25 of 28 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Liquidia Corporation leads opm at 46.3%; Amylyx Pharmaceuticals, Inc. leads margin change at +6111.6 percentage points.

LeaderLiquidia Corporation · 46.3%

Gap7.2% versus #2 · Indivior Pharmaceuticals, Inc.

Persistence4/8 recent comparable periods

Coverage25/28 companies · 471 observations

Investor read: Liquidia Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Liquidia Corporation LQDA46%

2Indivior Pharmaceuticals, Inc. INDV43%

3United Therapeutics Corporation UTHR42%

4Zoetis Inc. ZTS35%

5Teva Pharmaceutical Industries Limited TEVA34%

Margin changefastest expanders

1Amylyx Pharmaceuticals, Inc. AMLX+6,111.6 pp

2Liquidia Corporation LQDA+1,181.7 pp

3Viatris Inc. VTRS+86.3 pp

4Neurocrine Biosciences, Inc. NBIX+19.6 pp

5Indivior Pharmaceuticals, Inc. INDV+18.4 pp

Operating margin · company comparison

25/28 level · 26/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	OPM	Margin change	Reported
Liquidia Corporation LQDA	46%	+1,181.7 pp	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	43%	+18.4 pp	Mar 2026
United Therapeutics Corporation UTHR	42%	−6.5 pp	Mar 2026
Zoetis Inc. ZTS	35%	−1.5 pp	Mar 2026
Teva Pharmaceutical Industries Limited TEVA	34%	+4.2 pp	Mar 2026
Prestige Consumer Healthcare Inc. PBH	27%	−3.0 pp	Mar 2026
Neurocrine Biosciences, Inc. NBIX	24%	+19.6 pp	Mar 2026
Haleon plc HLN	22%	+9.1 pp	Dec 2025
Lantheus Holdings, Inc. LNTH	22%	−5.8 pp	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	20%	+5.2 pp	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	16%	+3.1 pp	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	14%	+4.1 pp	Mar 2026
Trulieve Cannabis Corp. TRLV	12%	+0.6 pp	Mar 2026
Phibro Animal Health Corporation PAHC	12%	+2.0 pp	Mar 2026
Elanco Animal Health Incorporated ELAN	11%	+2.1 pp	Mar 2026
Eton Pharmaceuticals, Inc. ETON	9.9%	+12.6 pp	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	9.5%	+14.6 pp	Mar 2026
Viatris Inc. VTRS	-2.3%	+86.3 pp	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	-4.0%	+2.8 pp	Mar 2026
Alkermes plc ALKS	-12%	−16.8 pp	Mar 2026
Hims & Hers Health, Inc. HIMS	-13%	−22.8 pp	Mar 2026
Bausch Health Companies Inc. BHC	-38%	−49.8 pp	Mar 2026
Perrigo Company plc PRGO	-38%	−42.9 pp	Mar 2026
Harrow, Inc. HROW	-50%	−26.5 pp	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	-138%	+6,111.6 pp	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	-449%	−463.2 pp	Mar 2026

Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021-6.7%

Dec 20214.3%

Mar 2022-9.5%

Jun 2022-13%

Sep 2022-24%

Dec 2022-1.8%

Mar 2023-3.8%

Jun 202346%

Sep 202323%

Dec 202315%

Mar 202412%

Jun 202428%

Sep 202428%

Dec 202438%

Mar 20254.5%

Jun 202524%

Sep 202523%

Dec 202515%

Mar 2026-12%

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021-6.2%

Dec 2021-6.3%

Mar 202210%

Jun 20224.5%

Sep 20221.6%

Dec 2022-2.7%

Mar 202314%

Jun 2023-0.5%

Sep 2023-96%

Dec 2023-5.8%

Mar 20246.5%

Jun 20242.8%

Sep 2024-2.2%

Dec 2024-0.5%

Mar 20258.4%

Jun 20255.9%

Sep 20250.2%

Dec 2025-16%

Mar 202611%

Jun 2026—

Haleon plc · HLN

Sep 202120%

Dec 202116%

Mar 202218%

Jun 202217%

Sep 202220%

Dec 202213%

Mar 202321%

Jun 202319%

Sep 202321%

Dec 20239.8%

Mar 202422%

Jun 202418%

Sep 202425%

Dec 202413%

Mar 202522%

Jun 202522%

Sep 202522%

Dec 202522%

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021-37%

Dec 2021-26%

Mar 2022-17%

Jun 2022-18%

Sep 2022-14%

Dec 2022-6.9%

Mar 2023-5.9%

Jun 2023-4.4%

Sep 2023-3.8%

Dec 2023-0.2%

Mar 20243.6%

Jun 20243.5%

Sep 20245.6%

Dec 20243.9%

Mar 20259.9%

Jun 20254.9%

Sep 20252.0%

Dec 20251.5%

Mar 2026-13%

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021-254%

Dec 2021-193%

Mar 2022-72%

Jun 2022-72%

Sep 202247%

Dec 20229.8%

Mar 2023-23%

Jun 2023-4.4%

Sep 2023-16%

Dec 20230.1%

Mar 2024-21%

Jun 2024-0.1%

Sep 2024-8.6%

Dec 2024-16%

Mar 20259.6%

Jun 202513%

Sep 202513%

Dec 20259.8%

Mar 202614%

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021-14%

Dec 2021-27%

Mar 202228%

Jun 202228%

Sep 202236%

Dec 2022-65%

Mar 2023-3.1%

Jun 202339%

Sep 202335%

Dec 202339%

Mar 202429%

Jun 202426%

Sep 202435%

Dec 202429%

Mar 202527%

Jun 202523%

Sep 202511%

Dec 202519%

Mar 202622%

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021-223%

Dec 2021-353%

Mar 2022-414%

Jun 2022-229%

Sep 2022-279%

Dec 2022-121%

Mar 2023-206%

Jun 2023-477%

Sep 2023-405%

Dec 2023-583%

Mar 2024-969%

Jun 2024-743%

Sep 2024-656%

Dec 2024—

Mar 2025—

Jun 2025-424%

Sep 20253.3%

Dec 202522%

Mar 202646%

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 202115%

Dec 2021-12%

Mar 20221.0%

Jun 202215%

Sep 202223%

Dec 202225%

Mar 2023-27%

Jun 202316%

Sep 202328%

Dec 202329%

Mar 202419%

Jun 202425%

Sep 202430%

Dec 202423%

Mar 20254.1%

Jun 202521%

Sep 202530%

Dec 202526%

Mar 202624%

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 202116%

Dec 20211.9%

Mar 2022-20%

Jun 2022-25%

Sep 202212%

Dec 2022-23%

Mar 2023-0.4%

Jun 2023-17%

Sep 20238.7%

Dec 202317%

Mar 2024-5.7%

Jun 2024-0.2%

Sep 2024-1.6%

Dec 2024-0.7%

Mar 202530%

Jun 202511%

Sep 202520%

Dec 20256.4%

Mar 202634%

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 202151%

Dec 202141%

Mar 202262%

Jun 202243%

Sep 202261%

Dec 202236%

Mar 202356%

Jun 202353%

Sep 202354%

Dec 202342%

Mar 202453%

Jun 202445%

Sep 202446%

Dec 202449%

Mar 202548%

Jun 202546%

Sep 202549%

Dec 202545%

Mar 202642%

Jun 2026—

Viatris Inc. · VTRS

Sep 20217.9%

Dec 2021-1.8%

Mar 202217%

Jun 202213%

Sep 202214%

Dec 2022-5.2%

Mar 202311%

Jun 20239.4%

Sep 202312%

Dec 2023-12%

Mar 20245.6%

Jun 2024-6.3%

Sep 20246.0%

Dec 2024-5.1%

Mar 2025-89%

Jun 20256.5%

Sep 20254.8%

Dec 2025-5.2%

Mar 2026-2.3%

Jun 2026—

Zoetis Inc. · ZTS

Sep 202136%

Dec 202130%

Mar 202240%

Jun 202235%

Sep 202236%

Dec 202234%

Mar 202335%

Jun 202338%

Sep 202336%

Dec 202332%

Mar 202436%

Jun 202437%

Sep 202438%

Dec 202433%

Mar 202537%

Jun 202539%

Sep 202539%

Dec 202534%

Mar 202635%

Jun 2026—

Margin change · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−14.0 pp

Sep 2022−17.3 pp

Dec 2022−6.1 pp

Mar 2023+5.7 pp

Jun 2023+58.1 pp

Sep 2023+47.4 pp

Dec 2023+16.3 pp

Mar 2024+16.2 pp

Jun 2024−18.1 pp

Sep 2024+4.3 pp

Dec 2024+23.3 pp

Mar 2025−7.9 pp

Jun 2025−3.7 pp

Sep 2025−5.1 pp

Dec 2025−22.7 pp

Mar 2026−16.8 pp

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+18.3 pp

Sep 2022+7.8 pp

Dec 2022+3.6 pp

Mar 2023+3.3 pp

Jun 2023−5.0 pp

Sep 2023−97.6 pp

Dec 2023−3.1 pp

Mar 2024−7.2 pp

Jun 2024+3.3 pp

Sep 2024+93.8 pp

Dec 2024+5.3 pp

Mar 2025+1.9 pp

Jun 2025+3.1 pp

Sep 2025+2.4 pp

Dec 2025−15.1 pp

Mar 2026+2.1 pp

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022+2.6 pp

Jun 2022−0.2 pp

Sep 2022−0.7 pp

Dec 2022−3.1 pp

Mar 2023+3.3 pp

Jun 2023+1.8 pp

Sep 2023+1.2 pp

Dec 2023−3.0 pp

Mar 2024+1.4 pp

Jun 2024−0.8 pp

Sep 2024+4.5 pp

Dec 2024+2.9 pp

Mar 2025−0.4 pp

Jun 2025+4.1 pp

Sep 2025−3.6 pp

Dec 2025+9.1 pp

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+10.9 pp

Sep 2022+23.5 pp

Dec 2022+18.6 pp

Mar 2023+10.8 pp

Jun 2023+13.4 pp

Sep 2023+10.0 pp

Dec 2023+6.7 pp

Mar 2024+9.5 pp

Jun 2024+7.9 pp

Sep 2024+9.4 pp

Dec 2024+4.1 pp

Mar 2025+6.3 pp

Jun 2025+1.4 pp

Sep 2025−3.6 pp

Dec 2025−2.4 pp

Mar 2026−22.8 pp

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+454.6 pp

Sep 2022+300.4 pp

Dec 2022+202.6 pp

Mar 2023+49.2 pp

Jun 2023+67.4 pp

Sep 2023−63.1 pp

Dec 2023−9.7 pp

Mar 2024+2.5 pp

Jun 2024+4.3 pp

Sep 2024+7.7 pp

Dec 2024−15.8 pp

Mar 2025+30.3 pp

Jun 2025+13.0 pp

Sep 2025+21.9 pp

Dec 2025+25.5 pp

Mar 2026+4.1 pp

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+54.8 pp

Sep 2022+49.8 pp

Dec 2022−37.9 pp

Mar 2023−31.3 pp

Jun 2023+10.3 pp

Sep 2023−0.7 pp

Dec 2023+104.0 pp

Mar 2024+31.9 pp

Jun 2024−12.5 pp

Sep 2024+0.2 pp

Dec 2024−9.7 pp

Mar 2025−1.4 pp

Jun 2025−2.8 pp

Sep 2025−23.9 pp

Dec 2025−10.1 pp

Mar 2026−5.8 pp

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−40.7 pp

Sep 2022−56.3 pp

Dec 2022+232.2 pp

Mar 2023+208.9 pp

Jun 2023−248.0 pp

Sep 2023−125.9 pp

Dec 2023−462.2 pp

Mar 2024−763.6 pp

Jun 2024−266.4 pp

Sep 2024−251.3 pp

Dec 2024−654.4 pp

Mar 2025−166.3 pp

Jun 2025+318.9 pp

Sep 2025+659.5 pp

Dec 2025+1,259.3 pp

Mar 2026+1,181.7 pp

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−7.2 pp

Sep 2022+7.6 pp

Dec 2022+36.7 pp

Mar 2023−28.2 pp

Jun 2023+1.8 pp

Sep 2023+5.7 pp

Dec 2023+4.1 pp

Mar 2024+46.5 pp

Jun 2024+8.3 pp

Sep 2024+1.2 pp

Dec 2024−6.6 pp

Mar 2025−15.2 pp

Jun 2025−3.4 pp

Sep 2025+0.6 pp

Dec 2025+3.6 pp

Mar 2026+19.6 pp

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−40.0 pp

Sep 2022−4.3 pp

Dec 2022−24.4 pp

Mar 2023+19.1 pp

Jun 2023+8.2 pp

Sep 2023−3.0 pp

Dec 2023+39.3 pp

Mar 2024−5.3 pp

Jun 2024+16.7 pp

Sep 2024−10.3 pp

Dec 2024−17.5 pp

Mar 2025+35.2 pp

Jun 2025+11.2 pp

Sep 2025+21.4 pp

Dec 2025+7.1 pp

Mar 2026+4.2 pp

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−6.6 pp

Sep 2022+9.5 pp

Dec 2022−5.2 pp

Mar 2023−6.3 pp

Jun 2023+9.3 pp

Sep 2023−7.2 pp

Dec 2023+6.6 pp

Mar 2024−3.5 pp

Jun 2024−7.8 pp

Sep 2024−7.9 pp

Dec 2024+6.3 pp

Mar 2025−4.4 pp

Jun 2025+0.9 pp

Sep 2025+2.8 pp

Dec 2025−3.5 pp

Mar 2026−6.5 pp

Jun 2026—

Viatris Inc. · VTRS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+14.3 pp

Sep 2022+5.8 pp

Dec 2022−3.4 pp

Mar 2023−6.2 pp

Jun 2023−3.9 pp

Sep 2023−2.2 pp

Dec 2023−6.6 pp

Mar 2024−5.1 pp

Jun 2024−15.7 pp

Sep 2024−5.5 pp

Dec 2024+6.7 pp

Mar 2025−94.2 pp

Jun 2025+12.8 pp

Sep 2025−1.2 pp

Dec 2025−0.1 pp

Mar 2026+86.3 pp

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−0.8 pp

Sep 2022−0.3 pp

Dec 2022+3.6 pp

Mar 2023−4.2 pp

Jun 2023+2.6 pp

Sep 2023+0.6 pp

Dec 2023−2.0 pp

Mar 2024+1.0 pp

Jun 2024−1.3 pp

Sep 2024+1.9 pp

Dec 2024+1.2 pp

Mar 2025+0.5 pp

Jun 2025+2.4 pp

Sep 2025+0.5 pp

Dec 2025+1.0 pp

Mar 2026−1.5 pp

Jun 2026—

03 · compare level, then change

Profit Scale & Acceleration

Zoetis Inc. has the highest Net profit among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $2,643 million. Haleon plc is next at $1,682 million. Amneal Pharmaceuticals, Inc. has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Zoetis Inc. leads with $2,643 million of TTM profit, 57.1% above Haleon plc. Amneal Pharmaceuticals, Inc. shows ≥100% on the scoring scale (451.5% uncapped) growth from a $182 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderZoetis Inc. · $2,643 million

Gap57.1% versus #2 · Haleon plc

Persistence6/8 recent comparable periods

Coverage26/28 companies · 508 observations

Investor read: Zoetis Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1Zoetis Inc. ZTS$2.6B

2Haleon plc HLN · older report$1.7B

3Teva Pharmaceutical Industries Limited TEVA$1.6B

4United Therapeutics Corporation UTHR$1.3B

5Neurocrine Biosciences, Inc. NBIX$670M

Profit growthfastest growers

1Amneal Pharmaceuticals, Inc. AMRX100%

2Neurocrine Biosciences, Inc. NBIX100%

3Phibro Animal Health Corporation PAHC100%

4Haleon plc HLN · older report14%

5Lantheus Holdings, Inc. LNTH9.8%

Net profit · company comparison

26/28 level · 11/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Net profit	Profit growth	Reported
Zoetis Inc. ZTS	$601M	-0.2%	Mar 2026
Haleon plc HLN	$434M	96%	Dec 2025
Teva Pharmaceutical Industries Limited TEVA	$370M	68%	Mar 2026
United Therapeutics Corporation UTHR	$275M	-15%	Mar 2026
Neurocrine Biosciences, Inc. NBIX	$198M	2,375%	Mar 2026
Viatris Inc. VTRS	$176M	-235%	Mar 2026
Lantheus Holdings, Inc. LNTH	$118M	62%	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	$115M	95%	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	$78M	212%	Mar 2026
Elanco Animal Health Incorporated ELAN	$57M	-15%	Mar 2026
Prestige Consumer Healthcare Inc. PBH	$54M	8.0%	Mar 2026
Liquidia Corporation LQDA	$53M	—	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	$29M	81%	Mar 2026
Phibro Animal Health Corporation PAHC	$24M	14%	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	$23M	156%	Mar 2026
Trulieve Cannabis Corp. TRLV	$2M	-705%	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	$2M	—	Mar 2026
Eton Pharmaceuticals, Inc. ETON	$2M	-300%	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	$-2M	-127%	Mar 2026
Regencell Bioscience Holdings Limited RGC	$-5M	—	Dec 2025
Harrow, Inc. HROW	$-28M	0.0%	Mar 2026
HUTCHMED (China) Limited HCM	$-37M	14,367%	Dec 2025
Amylyx Pharmaceuticals, Inc. AMLX	$-41M	-860%	Mar 2026
Alkermes plc ALKS	$-66M	-400%	Mar 2026
Hims & Hers Health, Inc. HIMS	$-92M	-288%	Mar 2026
Perrigo Company plc PRGO	$-390M	-100%	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	$-722M	—	Mar 2026
Bausch Health Companies Inc. BHC	$-1.4B	-174%	Mar 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021$-29M

Dec 2021$1M

Mar 2022$-45M

Jun 2022$-30M

Sep 2022$-67M

Dec 2022$-22M

Mar 2023$-12M

Jun 2023$279M

Sep 2023$92M

Dec 2023$161M

Mar 2024$39M

Jun 2024$95M

Sep 2024$93M

Dec 2024$146M

Mar 2025$22M

Jun 2025$87M

Sep 2025$83M

Dec 2025$49M

Mar 2026$-66M

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021$-104M

Dec 2021$-108M

Mar 2022$51M

Jun 2022$-10M

Sep 2022$-65M

Dec 2022$-54M

Mar 2023$103M

Jun 2023$-97M

Sep 2023$-1.1B

Dec 2023$-141M

Mar 2024$32M

Jun 2024$-50M

Sep 2024$364M

Dec 2024$-8M

Mar 2025$67M

Jun 2025$11M

Sep 2025$-34M

Dec 2025$-276M

Mar 2026$57M

Jun 2026—

Haleon plc · HLN

Sep 2021$382M

Dec 2021$537M

Mar 2022$357M

Jun 2022$187M

Sep 2022$365M

Dec 2022$210M

Mar 2023$415M

Jun 2023$315M

Sep 2023$374M

Dec 2023$7M

Mar 2024$441M

Jun 2024$313M

Sep 2024$499M

Dec 2024$222M

Mar 2025$407M

Jun 2025$407M

Sep 2025$434M

Dec 2025$434M

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021$-16M

Dec 2021$-31M

Mar 2022$-16M

Jun 2022$-20M

Sep 2022$-19M

Dec 2022$-11M

Mar 2023$-10M

Jun 2023$-7M

Sep 2023$-8M

Dec 2023$1M

Mar 2024$11M

Jun 2024$13M

Sep 2024$76M

Dec 2024$26M

Mar 2025$49M

Jun 2025$43M

Sep 2025$16M

Dec 2025$21M

Mar 2026$-92M

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021$-31M

Dec 2021$-36M

Mar 2022$-25M

Jun 2022$-20M

Sep 2022$224M

Dec 2022$4M

Mar 2023$-12M

Jun 2023$15M

Sep 2023$-14M

Dec 2023$25M

Mar 2024$-18M

Jun 2024$-4M

Sep 2024$-13M

Dec 2024$-9M

Mar 2025$9M

Jun 2025$18M

Sep 2025$18M

Dec 2025$14M

Mar 2026$23M

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021$-13M

Dec 2021$-40M

Mar 2022$43M

Jun 2022$43M

Sep 2022$61M

Dec 2022$-119M

Mar 2023$-3M

Jun 2023$94M

Sep 2023$132M

Dec 2023$103M

Mar 2024$131M

Jun 2024$62M

Sep 2024$131M

Dec 2024$-12M

Mar 2025$73M

Jun 2025$79M

Sep 2025$28M

Dec 2025$54M

Mar 2026$118M

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021$-7M

Dec 2021$-12M

Mar 2022$-16M

Jun 2022$-9M

Sep 2022$-9M

Dec 2022$-7M

Mar 2023$-12M

Jun 2023$-24M

Sep 2023$-16M

Dec 2023$-27M

Mar 2024$-30M

Jun 2024$-29M

Sep 2024$-31M

Dec 2024$-39M

Mar 2025$-38M

Jun 2025$-42M

Sep 2025$-4M

Dec 2025$15M

Mar 2026$53M

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021$23M

Dec 2021$-7M

Mar 2022$14M

Jun 2022$-17M

Sep 2022$69M

Dec 2022$89M

Mar 2023$-77M

Jun 2023$96M

Sep 2023$83M

Dec 2023$148M

Mar 2024$43M

Jun 2024$65M

Sep 2024$130M

Dec 2024$103M

Mar 2025$8M

Jun 2025$108M

Sep 2025$210M

Dec 2025$154M

Mar 2026$198M

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021$306M

Dec 2021$-151M

Mar 2022$-973M

Jun 2022$-260M

Sep 2022$59M

Dec 2022$-1.3B

Mar 2023$-253M

Jun 2023$-907M

Sep 2023$76M

Dec 2023$466M

Mar 2024$-415M

Jun 2024$-876M

Sep 2024$-393M

Dec 2024$-276M

Mar 2025$220M

Jun 2025$281M

Sep 2025$432M

Dec 2025$469M

Mar 2026$370M

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021$163M

Dec 2021$112M

Mar 2022$240M

Jun 2022$116M

Sep 2022$239M

Dec 2022$132M

Mar 2023$241M

Jun 2023$259M

Sep 2023$268M

Dec 2023$217M

Mar 2024$307M

Jun 2024$278M

Sep 2024$309M

Dec 2024$301M

Mar 2025$322M

Jun 2025$310M

Sep 2025$339M

Dec 2025$364M

Mar 2026$275M

Jun 2026—

Viatris Inc. · VTRS

Sep 2021$312M

Dec 2021$-264M

Mar 2022$399M

Jun 2022$314M

Sep 2022$354M

Dec 2022$1.0B

Mar 2023$225M

Jun 2023$264M

Sep 2023$332M

Dec 2023$-766M

Mar 2024$114M

Jun 2024$-326M

Sep 2024$95M

Dec 2024$-517M

Mar 2025$-3.0B

Jun 2025$-5M

Sep 2025$-128M

Dec 2025$-340M

Mar 2026$176M

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021$552M

Dec 2021$413M

Mar 2022$594M

Jun 2022$529M

Sep 2022$528M

Dec 2022$460M

Mar 2023$551M

Jun 2023$670M

Sep 2023$596M

Dec 2023$523M

Mar 2024$599M

Jun 2024$624M

Sep 2024$692M

Dec 2024$581M

Mar 2025$602M

Jun 2025$718M

Sep 2025$721M

Dec 2025$603M

Mar 2026$601M

Jun 2026—

Profit growth · reported quarter history

Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-1,600%

Sep 2022—

Dec 2022-2,300%

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024-66%

Sep 20241.1%

Dec 2024-9.3%

Mar 2025-44%

Jun 2025-8.4%

Sep 2025-11%

Dec 2025-66%

Mar 2026-400%

Jun 2026—

Amneal Pharmaceuticals, Inc. · AMRX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-850%

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024-43%

Sep 2024-52%

Dec 2024—

Mar 2025—

Jun 2025112%

Sep 202550%

Dec 2025—

Mar 2026212%

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023102%

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024-69%

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025109%

Jun 2025—

Sep 2025-109%

Dec 2025—

Mar 2026-15%

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 202243%

Jun 2022-31%

Sep 2022-4.5%

Dec 2022-61%

Mar 202316%

Jun 202368%

Sep 20232.5%

Dec 2023-97%

Mar 20246.3%

Jun 2024-0.6%

Sep 202433%

Dec 20243,071%

Mar 2025-7.7%

Jun 202530%

Sep 2025-13%

Dec 202596%

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 20242,500%

Mar 2025345%

Jun 2025231%

Sep 2025-79%

Dec 2025-19%

Mar 2026-288%

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023-106%

Dec 2023525%

Mar 2024—

Jun 2024-127%

Sep 2024—

Dec 2024-136%

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026156%

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023-107%

Jun 2023119%

Sep 2023116%

Dec 2023—

Mar 2024—

Jun 2024-34%

Sep 2024-0.8%

Dec 2024-112%

Mar 2025-44%

Jun 202527%

Sep 2025-79%

Dec 2025—

Mar 202662%

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-140%

Sep 2022200%

Dec 2022—

Mar 2023-650%

Jun 2023—

Sep 202320%

Dec 202366%

Mar 2024—

Jun 2024-32%

Sep 202457%

Dec 2024-30%

Mar 2025-81%

Jun 202566%

Sep 202562%

Dec 202550%

Mar 20262,375%

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-224%

Sep 2022-81%

Dec 2022—

Mar 2023—

Jun 2023—

Sep 202329%

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024-617%

Dec 2024-159%

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 202668%

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-33%

Sep 202247%

Dec 202218%

Mar 20230.4%

Jun 2023123%

Sep 202312%

Dec 202364%

Mar 202427%

Jun 20247.3%

Sep 202415%

Dec 202439%

Mar 20254.9%

Jun 202512%

Sep 20259.7%

Dec 202521%

Mar 2026-15%

Jun 2026—

Viatris Inc. · VTRS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202213%

Dec 2022—

Mar 2023-44%

Jun 2023-16%

Sep 2023-6.2%

Dec 2023-176%

Mar 2024-49%

Jun 2024-223%

Sep 2024-71%

Dec 2024—

Mar 2025-2,768%

Jun 2025—

Sep 2025-235%

Dec 2025—

Mar 2026—

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20223.5%

Sep 2022-4.4%

Dec 202211%

Mar 2023-7.2%

Jun 202327%

Sep 202313%

Dec 202314%

Mar 20248.7%

Jun 2024-6.9%

Sep 202416%

Dec 202411%

Mar 20250.5%

Jun 202515%

Sep 20254.2%

Dec 20253.8%

Mar 2026-0.2%

Jun 2026—

04 · compare level, then change

Capacity Spending & Returns On It

Teva Pharmaceutical Industries Limited has the highest CAPEX among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $168 million. Haleon plc is next at $113 million. United Therapeutics Corporation has the highest CAPEX intensity at 12.9%, so level and change sit with different companies. Its CAPEX series carries 19 reported observations across the 20-quarter window.

What the numbers say: Teva Pharmaceutical Industries Limited reports $168 million of CAPEX; United Therapeutics Corporation has the highest covered intensity at 12.9%. Coverage is only 28 of 28 companies and 485 reported observations, so this is partial evidence—not a complete sector rank.

LeaderTeva Pharmaceutical Industries Limited · $168 million

Gap48.7% versus #2 · Haleon plc

Persistence8/8 recent comparable periods

Coverage28/28 companies · 485 observations

Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.

This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.

CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.

CAPEXlargest spenders

1Teva Pharmaceutical Industries Limited TEVA$168M

2Haleon plc HLN · older report$113M

3Zoetis Inc. ZTS$110M

4Bausch Health Companies Inc. BHC$109M

5United Therapeutics Corporation UTHR$101M

CAPEX intensityhighest reinvestment intensity

1United Therapeutics Corporation UTHR13%

2Indivior Pharmaceuticals, Inc. INDV6.3%

3Hims & Hers Health, Inc. HIMS4.9%

4Zoetis Inc. ZTS4.9%

5Trulieve Cannabis Corp. TRLV4.5%

Capital expenditure · company comparison

28/28 level · 27/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	CAPEX	CAPEX intensity	Reported
Teva Pharmaceutical Industries Limited TEVA	$168M	4.2%	Mar 2026
Haleon plc HLN	$113M	4.1%	Dec 2025
Zoetis Inc. ZTS	$110M	4.9%	Mar 2026
Bausch Health Companies Inc. BHC	$109M	4.3%	Mar 2026
United Therapeutics Corporation UTHR	$101M	13%	Mar 2026
Elanco Animal Health Incorporated ELAN	$51M	3.7%	Mar 2026
Viatris Inc. VTRS	$40M	1.1%	Mar 2026
Hims & Hers Health, Inc. HIMS	$30M	4.9%	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	$20M	6.3%	Mar 2026
Phibro Animal Health Corporation PAHC	$15M	3.9%	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	$14M	1.9%	Mar 2026
Perrigo Company plc PRGO	$14M	1.4%	Mar 2026
Trulieve Cannabis Corp. TRLV	$13M	4.5%	Mar 2026
Neurocrine Biosciences, Inc. NBIX	$9M	1.1%	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	$6M	2.5%	Mar 2026
Prestige Consumer Healthcare Inc. PBH	$5M	1.8%	Mar 2026
HUTCHMED (China) Limited HCM	$5M	1.8%	Dec 2025
Alkermes plc ALKS	$4M	1.0%	Mar 2026
Liquidia Corporation LQDA	$3M	2.3%	Mar 2026
Lantheus Holdings, Inc. LNTH	$3M	0.8%	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	$0M	0.0%	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	$0M	0.0%	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	$0M	0.0%	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	$0M	0.0%	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	$0M	0.0%	Mar 2026
Harrow, Inc. HROW	$0M	0.0%	Mar 2026
Eton Pharmaceuticals, Inc. ETON	$0M	0.0%	Mar 2026

Full 20-quarter history · every available company

CAPEX · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021$5M

Dec 2021$9M

Mar 2022$8M

Jun 2022$10M

Sep 2022$10M

Dec 2022$10M

Mar 2023$7M

Jun 2023$10M

Sep 2023$14M

Dec 2023$17M

Mar 2024$8M

Jun 2024$7M

Sep 2024$8M

Dec 2024$10M

Mar 2025$10M

Jun 2025$13M

Sep 2025$17M

Dec 2025$0M

Mar 2026$4M

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021$25M

Dec 2021—

Mar 2022$19M

Jun 2022—

Sep 2022$36M

Dec 2022$77M

Mar 2023$24M

Jun 2023$42M

Sep 2023$33M

Dec 2023$41M

Mar 2024$24M

Jun 2024$34M

Sep 2024$42M

Dec 2024$47M

Mar 2025$65M

Jun 2025$57M

Sep 2025$92M

Dec 2025$62M

Mar 2026$51M

Jun 2026—

Haleon plc · HLN

Sep 2021$70M

Dec 2021$70M

Mar 2022$39M

Jun 2022$39M

Sep 2022$113M

Dec 2022$113M

Mar 2023$61M

Jun 2023$61M

Sep 2023$56M

Dec 2023$56M

Mar 2024$43M

Jun 2024$43M

Sep 2024$82M

Dec 2024$82M

Mar 2025$48M

Jun 2025$48M

Sep 2025$113M

Dec 2025$113M

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021$0M

Dec 2021$1M

Mar 2022$0M

Jun 2022$0M

Sep 2022$1M

Dec 2022$1M

Mar 2023$1M

Jun 2023$5M

Sep 2023$3M

Dec 2023$9M

Mar 2024$11M

Jun 2024$3M

Sep 2024$3M

Dec 2024$25M

Mar 2025$55M

Jun 2025$46M

Sep 2025$65M

Dec 2025$59M

Mar 2026$30M

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021$0M

Dec 2021$0M

Mar 2022—

Jun 2022$0M

Sep 2022$0M

Dec 2022$0M

Mar 2023$0M

Jun 2023$0M

Sep 2023$0M

Dec 2023$0M

Mar 2024$0M

Jun 2024$0M

Sep 2024$0M

Dec 2024$0M

Mar 2025$0M

Jun 2025$0M

Sep 2025$1M

Dec 2025$1M

Mar 2026$0M

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021$2M

Dec 2021$5M

Mar 2022$3M

Jun 2022$4M

Sep 2022$6M

Dec 2022$5M

Mar 2023$9M

Jun 2023$11M

Sep 2023$15M

Dec 2023$12M

Mar 2024$8M

Jun 2024$11M

Sep 2024$16M

Dec 2024$16M

Mar 2025$9M

Jun 2025$8M

Sep 2025$11M

Dec 2025$9M

Mar 2026$3M

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021$0M

Dec 2021$0M

Mar 2022—

Jun 2022$0M

Sep 2022$0M

Dec 2022$0M

Mar 2023$0M

Jun 2023$0M

Sep 2023$0M

Dec 2023$0M

Mar 2024$1M

Jun 2024$1M

Sep 2024$2M

Dec 2024$1M

Mar 2025$0M

Jun 2025$1M

Sep 2025$1M

Dec 2025$2M

Mar 2026$3M

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021$6M

Dec 2021$9M

Mar 2022$8M

Jun 2022$9M

Sep 2022$2M

Dec 2022$2M

Mar 2023$9M

Jun 2023$7M

Sep 2023$8M

Dec 2023$5M

Mar 2024$11M

Jun 2024$12M

Sep 2024$8M

Dec 2024$7M

Mar 2025$11M

Jun 2025$13M

Sep 2025$13M

Dec 2025$2M

Mar 2026$9M

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021$146M

Dec 2021$153M

Mar 2022$157M

Jun 2022$127M

Sep 2022$122M

Dec 2022$142M

Mar 2023$139M

Jun 2023$119M

Sep 2023$149M

Dec 2023$119M

Mar 2024$124M

Jun 2024$97M

Sep 2024$148M

Dec 2024$129M

Mar 2025$127M

Jun 2025$96M

Sep 2025$136M

Dec 2025$142M

Mar 2026$168M

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021$23M

Dec 2021$71M

Mar 2022$14M

Jun 2022$17M

Sep 2022$69M

Dec 2022$40M

Mar 2023$41M

Jun 2023$45M

Sep 2023$66M

Dec 2023$79M

Mar 2024$38M

Jun 2024$45M

Sep 2024$77M

Dec 2024$87M

Mar 2025$75M

Jun 2025$62M

Sep 2025$211M

Dec 2025$173M

Mar 2026$101M

Jun 2026—

Viatris Inc. · VTRS

Sep 2021$121M

Dec 2021$197M

Mar 2022$65M

Jun 2022$84M

Sep 2022$104M

Dec 2022$154M

Mar 2023$48M

Jun 2023$68M

Sep 2023$96M

Dec 2023$166M

Mar 2024$50M

Jun 2024$59M

Sep 2024$77M

Dec 2024$140M

Mar 2025$43M

Jun 2025$53M

Sep 2025$87M

Dec 2025$197M

Mar 2026$40M

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021$119M

Dec 2021$168M

Mar 2022$115M

Jun 2022$146M

Sep 2022$154M

Dec 2022$171M

Mar 2023$223M

Jun 2023$166M

Sep 2023$145M

Dec 2023$198M

Mar 2024$140M

Jun 2024$132M

Sep 2024$167M

Dec 2024$216M

Mar 2025$178M

Jun 2025$178M

Sep 2025$133M

Dec 2025$161M

Mar 2026$110M

Jun 2026—

CAPEX intensity · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 20211.7%

Dec 20212.8%

Mar 20222.9%

Jun 20223.6%

Sep 20224.0%

Dec 20223.3%

Mar 20232.4%

Jun 20231.6%

Sep 20233.7%

Dec 20234.5%

Mar 20242.3%

Jun 20241.8%

Sep 20242.1%

Dec 20242.3%

Mar 20253.3%

Jun 20253.3%

Sep 20254.3%

Dec 20250.0%

Mar 20261.0%

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 20212.2%

Dec 2021—

Mar 20221.5%

Jun 2022—

Sep 20223.5%

Dec 20227.8%

Mar 20231.9%

Jun 20234.0%

Sep 20233.1%

Dec 20234.0%

Mar 20242.0%

Jun 20242.9%

Sep 20244.1%

Dec 20244.6%

Mar 20255.4%

Jun 20254.6%

Sep 20258.1%

Dec 20255.4%

Mar 20263.7%

Jun 2026—

Haleon plc · HLN

Sep 20212.8%

Dec 20212.8%

Mar 20221.5%

Jun 20221.5%

Sep 20223.9%

Dec 20224.1%

Mar 20232.0%

Jun 20232.2%

Sep 20232.0%

Dec 20232.0%

Mar 20241.5%

Jun 20241.5%

Sep 20242.9%

Dec 20243.0%

Mar 20251.8%

Jun 20251.8%

Sep 20254.1%

Dec 20254.1%

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 20210.0%

Dec 20211.2%

Mar 20220.0%

Jun 20220.0%

Sep 20220.7%

Dec 20220.6%

Mar 20230.5%

Jun 20232.4%

Sep 20231.3%

Dec 20233.6%

Mar 20244.0%

Jun 20240.9%

Sep 20240.7%

Dec 20245.2%

Mar 20259.4%

Jun 20258.4%

Sep 202511%

Dec 20259.5%

Mar 20264.9%

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 20210.0%

Dec 20210.0%

Mar 2022—

Jun 20220.0%

Sep 20220.0%

Dec 20220.0%

Mar 20230.0%

Jun 20230.0%

Sep 20230.0%

Dec 20230.0%

Mar 20240.0%

Jun 20240.0%

Sep 20240.0%

Dec 20240.0%

Mar 20250.0%

Jun 20250.0%

Sep 20250.6%

Dec 20250.5%

Mar 20260.0%

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 20212.0%

Dec 20213.8%

Mar 20221.4%

Jun 20221.8%

Sep 20222.5%

Dec 20221.9%

Mar 20233.0%

Jun 20233.4%

Sep 20234.7%

Dec 20233.4%

Mar 20242.2%

Jun 20242.8%

Sep 20244.2%

Dec 20244.1%

Mar 20252.4%

Jun 20252.1%

Sep 20252.9%

Dec 20252.2%

Mar 20260.8%

Jun 2026—

Liquidia Corporation · LQDA

Sep 20210.0%

Dec 20210.0%

Mar 2022—

Jun 20220.0%

Sep 20220.0%

Dec 20220.0%

Mar 20230.0%

Jun 20230.0%

Sep 20230.0%

Dec 20230.0%

Mar 202433%

Jun 202425%

Sep 202450%

Dec 202433%

Mar 20250.0%

Jun 202511%

Sep 20251.9%

Dec 20252.2%

Mar 20262.3%

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 20212.0%

Dec 20212.9%

Mar 20222.6%

Jun 20222.4%

Sep 20220.5%

Dec 20220.5%

Mar 20232.1%

Jun 20231.5%

Sep 20231.6%

Dec 20231.0%

Mar 20242.1%

Jun 20242.0%

Sep 20241.3%

Dec 20241.1%

Mar 20251.9%

Jun 20251.9%

Sep 20251.6%

Dec 20250.2%

Mar 20261.1%

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 20213.8%

Dec 20213.7%

Mar 20224.3%

Jun 20223.4%

Sep 20223.4%

Dec 20223.7%

Mar 20233.8%

Jun 20233.1%

Sep 20233.9%

Dec 20232.7%

Mar 20243.2%

Jun 20242.3%

Sep 20243.4%

Dec 20243.1%

Mar 20253.3%

Jun 20252.3%

Sep 20253.0%

Dec 20253.0%

Mar 20264.2%

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 20215.2%

Dec 202117%

Mar 20223.0%

Jun 20223.6%

Sep 202213%

Dec 20228.1%

Mar 20238.1%

Jun 20237.5%

Sep 202311%

Dec 202313%

Mar 20245.6%

Jun 20246.3%

Sep 202410%

Dec 202412%

Mar 20259.4%

Jun 20257.8%

Sep 202526%

Dec 202522%

Mar 202613%

Jun 2026—

Viatris Inc. · VTRS

Sep 20212.7%

Dec 20214.5%

Mar 20221.6%

Jun 20222.0%

Sep 20222.6%

Dec 20224.0%

Mar 20231.3%

Jun 20231.7%

Sep 20232.4%

Dec 20234.3%

Mar 20241.4%

Jun 20241.6%

Sep 20242.1%

Dec 20244.0%

Mar 20251.3%

Jun 20251.5%

Sep 20252.3%

Dec 20255.3%

Mar 20261.1%

Jun 2026—

Zoetis Inc. · ZTS

Sep 20216.0%

Dec 20218.5%

Mar 20225.8%

Jun 20227.1%

Sep 20227.7%

Dec 20228.4%

Mar 202311%

Jun 20237.6%

Sep 20236.7%

Dec 20238.9%

Mar 20246.4%

Jun 20245.6%

Sep 20247.0%

Dec 20249.3%

Mar 20258.1%

Jun 20257.2%

Sep 20255.5%

Dec 20256.7%

Mar 20264.9%

Jun 2026—

Annual capital allocation · 6-year view

28/28 capacity base · 28/28 OCF · 28/28 CAPEX · 28/28 FCF

Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.

Full annual capacity base, operating cash flow, CAPEX and free cash flow history

Capacity base · net fixed assets + CWIP · fiscal-year history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Jun 2021—

Dec 2021$457M

Dec 2022$320M

Dec 2023$318M

Dec 2024$312M

Dec 2025$299M

Elanco Animal Health Incorporated · ELAN

Jun 2021—

Dec 2021$1.1B

Dec 2022$999M

Dec 2023$1.0B

Dec 2024$993M

Dec 2025$1.4B

Haleon plc · HLN

Jun 2021—

Dec 2021$1.7B

Dec 2022$1.9B

Dec 2023$1.9B

Dec 2024$1.9B

Dec 2025$2.0B

Hims & Hers Health, Inc. · HIMS

Jun 2021—

Dec 2021$5M

Dec 2022$16M

Dec 2023$46M

Dec 2024$93M

Dec 2025$449M

Kiniksa Pharmaceuticals International, plc · KNSA

Jun 2021—

Dec 2021$8M

Dec 2022$7M

Dec 2023$13M

Dec 2024$11M

Dec 2025$12M

Lantheus Holdings, Inc. · LNTH

Jun 2021—

Dec 2021$117M

Dec 2022$122M

Dec 2023$147M

Dec 2024$177M

Dec 2025$164M

Liquidia Corporation · LQDA

Jun 2021—

Dec 2021$7M

Dec 2022$6M

Dec 2023$6M

Dec 2024$12M

Dec 2025$16M

Neurocrine Biosciences, Inc. · NBIX

Jun 2021—

Dec 2021$156M

Dec 2022$146M

Dec 2023$347M

Dec 2024$592M

Dec 2025$545M

Teva Pharmaceutical Industries Limited · TEVA

Jun 2021—

Dec 2021$6.5B

Dec 2022$6.2B

Dec 2023$6.1B

Dec 2024$4.9B

Dec 2025$4.4B

United Therapeutics Corporation · UTHR

Jun 2021—

Dec 2021$781M

Dec 2022$862M

Dec 2023$1.0B

Dec 2024$1.2B

Dec 2025$1.7B

Viatris Inc. · VTRS

Jun 2021—

Dec 2021$3.2B

Dec 2022$3.0B

Dec 2023$2.8B

Dec 2024$2.7B

Dec 2025$2.6B

Zoetis Inc. · ZTS

Jun 2021—

Dec 2021$2.6B

Dec 2022$3.0B

Dec 2023$3.4B

Dec 2024$3.6B

Dec 2025$4.0B

Operating cash flow · fiscal-year history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Jun 2021—

Dec 2021$102M

Dec 2022$21M

Dec 2023$401M

Dec 2024$439M

Dec 2025$521M

Elanco Animal Health Incorporated · ELAN

Jun 2021—

Dec 2021$483M

Dec 2022$452M

Dec 2023$271M

Dec 2024$541M

Dec 2025$560M

Haleon plc · HLN

Jun 2021—

Dec 2021$1.4B

Dec 2022$2.1B

Dec 2023$2.1B

Dec 2024$2.3B

Dec 2025$2.6B

Hims & Hers Health, Inc. · HIMS

Jun 2021—

Dec 2021$-34M

Dec 2022$-27M

Dec 2023$73M

Dec 2024$251M

Dec 2025$300M

Kiniksa Pharmaceuticals International, plc · KNSA

Jun 2021—

Dec 2021$-126M

Dec 2022$6M

Dec 2023$13M

Dec 2024$26M

Dec 2025$138M

Lantheus Holdings, Inc. · LNTH

Jun 2021—

Dec 2021$54M

Dec 2022$282M

Dec 2023$305M

Dec 2024$545M

Dec 2025$390M

Liquidia Corporation · LQDA

Jun 2021—

Dec 2021$-34M

Dec 2022$-29M

Dec 2023$-42M

Dec 2024$-93M

Dec 2025$-36M

Neurocrine Biosciences, Inc. · NBIX

Jun 2021—

Dec 2021$257M

Dec 2022$339M

Dec 2023$390M

Dec 2024$595M

Dec 2025$783M

Teva Pharmaceutical Industries Limited · TEVA

Jun 2021—

Dec 2021$798M

Dec 2022$1.6B

Dec 2023$1.4B

Dec 2024$1.2B

Dec 2025$1.6B

United Therapeutics Corporation · UTHR

Jun 2021—

Dec 2021$598M

Dec 2022$803M

Dec 2023$978M

Dec 2024$1.3B

Dec 2025$1.6B

Viatris Inc. · VTRS

Jun 2021—

Dec 2021$3.0B

Dec 2022$3.0B

Dec 2023$2.9B

Dec 2024$2.3B

Dec 2025$2.3B

Zoetis Inc. · ZTS

Jun 2021—

Dec 2021$2.2B

Dec 2022$1.9B

Dec 2023$2.4B

Dec 2024$3.0B

Dec 2025$2.9B

CAPEX · reported cash flow · fiscal-year history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Jun 2021—

Dec 2021$28M

Dec 2022$38M

Dec 2023$48M

Dec 2024$33M

Dec 2025$40M

Elanco Animal Health Incorporated · ELAN

Jun 2021—

Dec 2021$159M

Dec 2022$171M

Dec 2023$140M

Dec 2024$147M

Dec 2025$276M

Haleon plc · HLN

Jun 2021—

Dec 2021$228M

Dec 2022$304M

Dec 2023$234M

Dec 2024$250M

Dec 2025$322M

Hims & Hers Health, Inc. · HIMS

Jun 2021—

Dec 2021$1M

Dec 2022$3M

Dec 2023$17M

Dec 2024$42M

Dec 2025$226M

Kiniksa Pharmaceuticals International, plc · KNSA

Jun 2021—

Dec 2021$0M

Dec 2022$0M

Dec 2023$0M

Dec 2024$0M

Dec 2025$2M

Lantheus Holdings, Inc. · LNTH

Jun 2021—

Dec 2021$12M

Dec 2022$18M

Dec 2023$47M

Dec 2024$52M

Dec 2025$36M

Liquidia Corporation · LQDA

Jun 2021—

Dec 2021$0M

Dec 2022$1M

Dec 2023$1M

Dec 2024$5M

Dec 2025$4M

Neurocrine Biosciences, Inc. · NBIX

Jun 2021—

Dec 2021$23M

Dec 2022$17M

Dec 2023$28M

Dec 2024$38M

Dec 2025$34M

Teva Pharmaceutical Industries Limited · TEVA

Jun 2021—

Dec 2021$562M

Dec 2022$548M

Dec 2023$526M

Dec 2024$498M

Dec 2025$501M

United Therapeutics Corporation · UTHR

Jun 2021—

Dec 2021$121M

Dec 2022$139M

Dec 2023$230M

Dec 2024$247M

Dec 2025$521M

Viatris Inc. · VTRS

Jun 2021—

Dec 2021$457M

Dec 2022$406M

Dec 2023$377M

Dec 2024$326M

Dec 2025$379M

Zoetis Inc. · ZTS

Jun 2021—

Dec 2021$477M

Dec 2022$586M

Dec 2023$732M

Dec 2024$655M

Dec 2025$621M

Free cash flow · fiscal-year history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Jun 2021—

Dec 2021$74M

Dec 2022$-17M

Dec 2023$353M

Dec 2024$406M

Dec 2025$480M

Elanco Animal Health Incorporated · ELAN

Jun 2021—

Dec 2021$324M

Dec 2022$281M

Dec 2023$131M

Dec 2024$394M

Dec 2025$284M

Haleon plc · HLN

Jun 2021—

Dec 2021$1.1B

Dec 2022$1.8B

Dec 2023$1.9B

Dec 2024$2.1B

Dec 2025$2.3B

Hims & Hers Health, Inc. · HIMS

Jun 2021—

Dec 2021$-35M

Dec 2022$-29M

Dec 2023$56M

Dec 2024$209M

Dec 2025$74M

Kiniksa Pharmaceuticals International, plc · KNSA

Jun 2021—

Dec 2021$-127M

Dec 2022$6M

Dec 2023$13M

Dec 2024$25M

Dec 2025$136M

Lantheus Holdings, Inc. · LNTH

Jun 2021—

Dec 2021$42M

Dec 2022$263M

Dec 2023$259M

Dec 2024$493M

Dec 2025$354M

Liquidia Corporation · LQDA

Jun 2021—

Dec 2021$-34M

Dec 2022$-29M

Dec 2023$-43M

Dec 2024$-98M

Dec 2025$-40M

Neurocrine Biosciences, Inc. · NBIX

Jun 2021—

Dec 2021$233M

Dec 2022$323M

Dec 2023$362M

Dec 2024$557M

Dec 2025$749M

Teva Pharmaceutical Industries Limited · TEVA

Jun 2021—

Dec 2021$236M

Dec 2022$1.0B

Dec 2023$842M

Dec 2024$749M

Dec 2025$1.1B

United Therapeutics Corporation · UTHR

Jun 2021—

Dec 2021$477M

Dec 2022$664M

Dec 2023$748M

Dec 2024$1.1B

Dec 2025$1.0B

Viatris Inc. · VTRS

Jun 2021—

Dec 2021$2.6B

Dec 2022$2.6B

Dec 2023$2.5B

Dec 2024$2.0B

Dec 2025$1.9B

Zoetis Inc. · ZTS

Jun 2021—

Dec 2021$1.7B

Dec 2022$1.3B

Dec 2023$1.6B

Dec 2024$2.3B

Dec 2025$2.3B

05 · compare level, then change

Debt Load & Balance-Sheet Headroom

United Therapeutics Corporation has the lowest Gross debt among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $0 million. Amylyx Pharmaceuticals, Inc. is next at $6 million. The same company also holds the lowest Net debt, at $2,154 million net cash. 26 of 28 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: United Therapeutics Corporation has the clearest covered balance-sheet capacity with $2,154 million net cash and gross debt of $0 million. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.

LeaderUnited Therapeutics Corporation · $0 million

Gap100% versus #2 · Amylyx Pharmaceuticals, Inc.

Persistence8/8 recent comparable periods

Coverage26/28 companies · 491 observations

Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.

This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.

Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.

Gross debtlowest gross debt

1United Therapeutics Corporation UTHR$0M

2Amylyx Pharmaceuticals, Inc. AMLX$6M

3Kiniksa Pharmaceuticals International, plc KNSA$9M

4Supernus Pharmaceuticals, Inc. SUPN$30M

5Eton Pharmaceuticals, Inc. ETON$31M

Net debtlowest net debt

1United Therapeutics Corporation UTHR$-2.2B

2Neurocrine Biosciences, Inc. NBIX$-910M

3Kiniksa Pharmaceuticals International, plc KNSA$-459M

4Supernus Pharmaceuticals, Inc. SUPN$-354M

5Amylyx Pharmaceuticals, Inc. AMLX$-274M

Debt and balance-sheet capacity · company comparison

26/28 level · 26/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Gross debt	Net debt	Reported
Bausch Health Companies Inc. BHC	$20.8B	$19.5B	Mar 2026
Teva Pharmaceutical Industries Limited TEVA	$16.9B	$13.2B	Mar 2026
Viatris Inc. VTRS	$14.3B	$12.5B	Mar 2026
Zoetis Inc. ZTS	$9.2B	$7.3B	Mar 2026
Haleon plc HLN	$8.6B	$7.3B	Dec 2025
Elanco Animal Health Incorporated ELAN	$4.0B	$3.6B	Mar 2026
Perrigo Company plc PRGO	$3.6B	$3.3B	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	$2.7B	$2.5B	Mar 2026
Alkermes plc ALKS	$1.6B	$1.1B	Mar 2026
Hims & Hers Health, Inc. HIMS	$1.1B	$381M	Mar 2026
Prestige Consumer Healthcare Inc. PBH	$1.0B	$978M	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	$863M	$625M	Mar 2026
Phibro Animal Health Corporation PAHC	$736M	$659M	Mar 2026
Trulieve Cannabis Corp. TRLV	$630M	$277M	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	$614M	$288M	Mar 2026
Lantheus Holdings, Inc. LNTH	$570M	$71M	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	$509M	$334M	Mar 2026
Neurocrine Biosciences, Inc. NBIX	$406M	$-910M	Mar 2026
Harrow, Inc. HROW	$301M	$206M	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	$259M	$147M	Mar 2026
Liquidia Corporation LQDA	$185M	$-38M	Mar 2026
Eton Pharmaceuticals, Inc. ETON	$31M	$11M	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	$30M	$-354M	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	$9M	$-459M	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	$6M	$-274M	Mar 2026
United Therapeutics Corporation UTHR	$0M	$-2.2B	Mar 2026

Full 20-quarter history · every available company

Gross debt · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021$420M

Dec 2021$416M

Mar 2022$415M

Jun 2022$410M

Sep 2022$405M

Dec 2022$379M

Mar 2023$394M

Jun 2023$390M

Sep 2023$385M

Dec 2023$372M

Mar 2024$370M

Jun 2024$368M

Sep 2024$366M

Dec 2024$76M

Mar 2025$74M

Jun 2025$73M

Sep 2025$72M

Dec 2025$70M

Mar 2026$1.6B

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021$6.3B

Dec 2021$6.3B

Mar 2022$6.1B

Jun 2022$6.1B

Sep 2022$5.9B

Dec 2022$5.8B

Mar 2023$6.0B

Jun 2023$6.1B

Sep 2023$5.9B

Dec 2023$5.8B

Mar 2024$5.8B

Jun 2024$5.7B

Sep 2024$4.4B

Dec 2024$4.3B

Mar 2025$4.4B

Jun 2025$4.2B

Sep 2025$4.0B

Dec 2025$4.0B

Mar 2026$4.0B

Jun 2026—

Haleon plc · HLN

Sep 2021$166M

Dec 2021$166M

Mar 2022$9.4B

Jun 2022$10.3B

Sep 2022$10.4B

Dec 2022$10.4B

Mar 2023$9.9B

Jun 2023$9.9B

Sep 2023$9.5B

Dec 2023$9.5B

Mar 2024$8.9B

Jun 2024$8.9B

Sep 2024$10.1B

Dec 2024$10.1B

Mar 2025$8.5B

Jun 2025$8.5B

Sep 2025$8.6B

Dec 2025$8.6B

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021$0M

Dec 2021$5M

Mar 2022$5M

Jun 2022$5M

Sep 2022$6M

Dec 2022$5M

Mar 2023$5M

Jun 2023$5M

Sep 2023$5M

Dec 2023$10M

Mar 2024$12M

Jun 2024$11M

Sep 2024$11M

Dec 2024$11M

Mar 2025$63M

Jun 2025$1.0B

Sep 2025$1.1B

Dec 2025$1.1B

Mar 2026$1.1B

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021$7M

Dec 2021$6M

Mar 2022$5M

Jun 2022$5M

Sep 2022$7M

Dec 2022$6M

Mar 2023$6M

Jun 2023$14M

Sep 2023$13M

Dec 2023$12M

Mar 2024$12M

Jun 2024$11M

Sep 2024$11M

Dec 2024$10M

Mar 2025$10M

Jun 2025$10M

Sep 2025$10M

Dec 2025$9M

Mar 2026$9M

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021$177M

Dec 2021$175M

Mar 2022$172M

Jun 2022$170M

Sep 2022$167M

Dec 2022$558M

Mar 2023$559M

Jun 2023$560M

Sep 2023$561M

Dec 2023$562M

Mar 2024$563M

Jun 2024$564M

Sep 2024$565M

Dec 2024$566M

Mar 2025$567M

Jun 2025$568M

Sep 2025$569M

Dec 2025$569M

Mar 2026$570M

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021$16M

Dec 2021$16M

Mar 2022$25M

Jun 2022$25M

Sep 2022$25M

Dec 2022$24M

Mar 2023$37M

Jun 2023$38M

Sep 2023$48M

Dec 2023$50M

Mar 2024$88M

Jun 2024$89M

Sep 2024$116M

Dec 2024$120M

Mar 2025$148M

Jun 2025$200M

Sep 2025$199M

Dec 2025$198M

Mar 2026$185M

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021$437M

Dec 2021$440M

Mar 2022$480M

Jun 2022$269M

Sep 2022$266M

Dec 2022$263M

Mar 2023$260M

Jun 2023$259M

Sep 2023$256M

Dec 2023$428M

Mar 2024$376M

Jun 2024$256M

Sep 2024$251M

Dec 2024$455M

Mar 2025$448M

Jun 2025$439M

Sep 2025$428M

Dec 2025$415M

Mar 2026$406M

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021$24.2B

Dec 2021$23.5B

Mar 2022$23.3B

Jun 2022$22.5B

Sep 2022$21.6B

Dec 2022$21.6B

Mar 2023$21.0B

Jun 2023$21.0B

Sep 2023$20.3B

Dec 2023$20.2B

Mar 2024$19.9B

Jun 2024$18.9B

Sep 2024$19.3B

Dec 2024$18.1B

Mar 2025$16.9B

Jun 2025$17.5B

Sep 2025$17.1B

Dec 2025$17.1B

Mar 2026$16.9B

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021$800M

Dec 2021$800M

Mar 2022$800M

Jun 2022$800M

Sep 2022$800M

Dec 2022$800M

Mar 2023$800M

Jun 2023$800M

Sep 2023$800M

Dec 2023$700M

Mar 2024$600M

Jun 2024$500M

Sep 2024$400M

Dec 2024$300M

Mar 2025$200M

Jun 2025$0M

Sep 2025$0M

Dec 2025$0M

Mar 2026$0M

Jun 2026—

Viatris Inc. · VTRS

Sep 2021$23.5B

Dec 2021$23.1B

Mar 2022$22.0B

Jun 2022$21.0B

Sep 2022$20.0B

Dec 2022$19.3B

Mar 2023$18.8B

Jun 2023$18.6B

Sep 2023$18.4B

Dec 2023$18.1B

Mar 2024$18.0B

Jun 2024$17.1B

Sep 2024$15.8B

Dec 2024$14.0B

Mar 2025$14.2B

Jun 2025$14.5B

Sep 2025$14.4B

Dec 2025$14.4B

Mar 2026$14.3B

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021$6.8B

Dec 2021$6.7B

Mar 2022$6.7B

Jun 2022$6.7B

Sep 2022$6.7B

Dec 2022$8.1B

Mar 2023$6.7B

Jun 2023$6.7B

Sep 2023$6.7B

Dec 2023$6.8B

Mar 2024$6.8B

Jun 2024$6.7B

Sep 2024$6.8B

Dec 2024$6.7B

Mar 2025$6.8B

Jun 2025$6.8B

Sep 2025$7.3B

Dec 2025$9.2B

Mar 2026$9.2B

Jun 2026—

Net debt · reported quarter history

Showing the 12 largest of 26 companies with a series here. The remaining 14 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021$-140M

Dec 2021$-120M

Mar 2022$-114M

Jun 2022$-171M

Sep 2022$-175M

Dec 2022$-229M

Mar 2023$-206M

Jun 2023$-439M

Sep 2023$-504M

Dec 2023$-401M

Mar 2024$-375M

Jun 2024$-508M

Sep 2024$-543M

Dec 2024$-676M

Mar 2025$-810M

Jun 2025$-943M

Sep 2025$-1.0B

Dec 2025$-518M

Mar 2026$1.1B

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021$5.9B

Dec 2021$5.7B

Mar 2022$5.8B

Jun 2022$5.6B

Sep 2022$5.4B

Dec 2022$5.5B

Mar 2023$5.7B

Jun 2023$5.7B

Sep 2023$5.5B

Dec 2023$5.4B

Mar 2024$5.4B

Jun 2024$5.3B

Sep 2024$3.9B

Dec 2024$3.9B

Mar 2025$3.9B

Jun 2025$3.7B

Sep 2025$3.5B

Dec 2025$3.5B

Mar 2026$3.6B

Jun 2026—

Haleon plc · HLN

Sep 2021$-248M

Dec 2021$-248M

Mar 2022$9.1B

Jun 2022$8.9B

Sep 2022$9.8B

Dec 2022$9.8B

Mar 2023$9.4B

Jun 2023$9.4B

Sep 2023$8.4B

Dec 2023$8.4B

Mar 2024$8.3B

Jun 2024$8.3B

Sep 2024$7.9B

Dec 2024$7.9B

Mar 2025$7.8B

Jun 2025$7.8B

Sep 2025$7.3B

Dec 2025$7.3B

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021$-252M

Dec 2021$-242M

Mar 2022$-198M

Jun 2022$-190M

Sep 2022$-192M

Dec 2022$-175M

Mar 2023$-179M

Jun 2023$-188M

Sep 2023$-207M

Dec 2023$-211M

Mar 2024$-192M

Jun 2024$-216M

Sep 2024$-243M

Dec 2024$-289M

Mar 2025$-260M

Jun 2025$-101M

Sep 2025$488M

Dec 2025$544M

Mar 2026$381M

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021$-193M

Dec 2021$-176M

Mar 2022$-141M

Jun 2022$-133M

Sep 2022$-194M

Dec 2022$-185M

Mar 2023$-181M

Jun 2023$-171M

Sep 2023$-188M

Dec 2023$-194M

Mar 2024$-202M

Jun 2024$-208M

Sep 2024$-213M

Dec 2024$-234M

Mar 2025$-258M

Jun 2025$-298M

Sep 2025$-342M

Dec 2025$-405M

Mar 2026$-459M

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021$86M

Dec 2021$76M

Mar 2022$67M

Jun 2022$-1M

Sep 2022$-90M

Dec 2022$142M

Mar 2023$88M

Jun 2023$146M

Sep 2023$-53M

Dec 2023$-152M

Mar 2024$-155M

Jun 2024$-193M

Sep 2024$-301M

Dec 2024$-347M

Mar 2025$-372M

Jun 2025$-128M

Sep 2025$187M

Dec 2025$210M

Mar 2026$71M

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021$-48M

Dec 2021$-41M

Mar 2022$-33M

Jun 2022$-79M

Sep 2022$-73M

Dec 2022$-69M

Mar 2023$-57M

Jun 2023$-50M

Sep 2023$-28M

Dec 2023$-34M

Mar 2024$-70M

Jun 2024$-44M

Sep 2024$-88M

Dec 2024$-56M

Mar 2025$-22M

Jun 2025$27M

Sep 2025$42M

Dec 2025$7M

Mar 2026$-38M

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021$-329M

Dec 2021$-271M

Mar 2022$-185M

Jun 2022$-379M

Sep 2022$-533M

Dec 2022$-726M

Mar 2023$-635M

Jun 2023$-718M

Sep 2023$-839M

Dec 2023$-604M

Mar 2024$-835M

Jun 2024$-783M

Sep 2024$-977M

Dec 2024$-621M

Mar 2025$-496M

Jun 2025$-537M

Sep 2025$-687M

Dec 2025$-1.1B

Mar 2026$-910M

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021$22.1B

Dec 2021$21.3B

Mar 2022$21.1B

Jun 2022$20.4B

Sep 2022$19.4B

Dec 2022$18.8B

Mar 2023$18.9B

Jun 2023$18.3B

Sep 2023$18.0B

Dec 2023$16.9B

Mar 2024$16.9B

Jun 2024$16.7B

Sep 2024$16.0B

Dec 2024$14.8B

Mar 2025$15.2B

Jun 2025$15.4B

Sep 2025$14.9B

Dec 2025$13.5B

Mar 2026$13.2B

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021$-1.2B

Dec 2021$-1.1B

Mar 2022$-1.5B

Jun 2022$-1.5B

Sep 2022$-1.8B

Dec 2022$-2.0B

Mar 2023$-2.1B

Jun 2023$-1.9B

Sep 2023$-2.1B

Dec 2023$-2.3B

Mar 2024$-2.1B

Jun 2024$-2.5B

Sep 2024$-2.9B

Dec 2024$-3.0B

Mar 2025$-3.1B

Jun 2025$-3.0B

Sep 2025$-2.8B

Dec 2025$-2.9B

Mar 2026$-2.2B

Jun 2026—

Viatris Inc. · VTRS

Sep 2021$22.7B

Dec 2021$22.4B

Mar 2022$21.3B

Jun 2022$20.3B

Sep 2022$19.3B

Dec 2022$18.0B

Mar 2023$18.3B

Jun 2023$18.0B

Sep 2023$17.1B

Dec 2023$17.1B

Mar 2024$17.0B

Jun 2024$16.2B

Sep 2024$13.9B

Dec 2024$13.3B

Mar 2025$13.4B

Jun 2025$13.9B

Sep 2025$13.5B

Dec 2025$13.1B

Mar 2026$12.5B

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021$3.5B

Dec 2021$3.3B

Mar 2022$3.6B

Jun 2022$4.1B

Sep 2022$4.2B

Dec 2022$4.5B

Mar 2023$4.6B

Jun 2023$5.0B

Sep 2023$5.0B

Dec 2023$4.7B

Mar 2024$4.8B

Jun 2024$5.2B

Sep 2024$5.0B

Dec 2024$4.8B

Mar 2025$5.0B

Jun 2025$5.4B

Sep 2025$5.2B

Dec 2025$6.9B

Mar 2026$7.3B

Jun 2026—

06 · compare level, then change

Return On Capital Employed

Indivior Pharmaceuticals, Inc. has the highest ROCE among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 34.8%. Liquidia Corporation is next at 29.4%. Liquidia Corporation has the highest ROCE change at +50.1 percentage points, so level and change sit with different companies. 28 of 28 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Indivior Pharmaceuticals, Inc. leads ROCE at 34.8%, 5.4 percentage points above Liquidia Corporation. Liquidia Corporation has the strongest latest improvement at +50.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderIndivior Pharmaceuticals, Inc. · 34.8%

Gap18.4% versus #2 · Liquidia Corporation

Persistence7/8 recent comparable periods

Coverage28/28 companies · 525 observations

Investor read: Indivior Pharmaceuticals, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1Indivior Pharmaceuticals, Inc. INDV35%

2Liquidia Corporation LQDA29%

3Zoetis Inc. ZTS6.7%

4Amneal Pharmaceuticals, Inc. AMRX5.6%

5Trulieve Cannabis Corp. TRLV5.6%

ROCE changefastest improvers

1Liquidia Corporation LQDA+50.1 pp

2Indivior Pharmaceuticals, Inc. INDV+29.9 pp

3Viatris Inc. VTRS+7.7 pp

4Eton Pharmaceuticals, Inc. ETON+5.6 pp

5Neurocrine Biosciences, Inc. NBIX+4.5 pp

Return on capital · company comparison

28/28 level · 28/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	ROCE	ROCE change	Reported
Indivior Pharmaceuticals, Inc. INDV	35%	+29.9 pp	Mar 2026
Liquidia Corporation LQDA	29%	+50.1 pp	Mar 2026
Zoetis Inc. ZTS	6.7%	−0.3 pp	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	5.6%	+1.5 pp	Mar 2026
Trulieve Cannabis Corp. TRLV	5.6%	+2.6 pp	Mar 2026
Neurocrine Biosciences, Inc. NBIX	5.3%	+4.5 pp	Mar 2026
United Therapeutics Corporation UTHR	5.0%	−1.0 pp	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	5.0%	+2.2 pp	Mar 2026
Lantheus Holdings, Inc. LNTH	4.3%	−1.7 pp	Mar 2026
Eton Pharmaceuticals, Inc. ETON	4.3%	+5.6 pp	Mar 2026
Phibro Animal Health Corporation PAHC	4.0%	+0.4 pp	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	3.4%	+0.6 pp	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	3.2%	+4.5 pp	Mar 2026
Teva Pharmaceutical Industries Limited TEVA	2.4%	+0.6 pp	Mar 2026
Prestige Consumer Healthcare Inc. PBH	2.3%	−0.4 pp	Mar 2026
Haleon plc HLN	2.2%	+1.0 pp	Dec 2025
Elanco Animal Health Incorporated ELAN	1.2%	+0.4 pp	Mar 2026
Viatris Inc. VTRS	-0.3%	+7.7 pp	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	-0.8%	+0.2 pp	Mar 2026
HUTCHMED (China) Limited HCM	-1.5%	−0.6 pp	Dec 2025
Alkermes plc ALKS	-1.8%	−2.6 pp	Mar 2026
Bausch Health Companies Inc. BHC	-4.5%	−5.7 pp	Mar 2026
Perrigo Company plc PRGO	-4.8%	−5.3 pp	Mar 2026
Hims & Hers Health, Inc. HIMS	-6.9%	−18.9 pp	Mar 2026
Harrow, Inc. HROW	-8.7%	−3.5 pp	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	-18%	−4.0 pp	Mar 2026
Regencell Bioscience Holdings Limited RGC	-61%	−49.5 pp	Dec 2025
BioCryst Pharmaceuticals, Inc. BCRX	-230%	−236.3 pp	Mar 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021-1.3%

Dec 20210.9%

Mar 2022-1.8%

Jun 2022-2.2%

Sep 2022-4.0%

Dec 2022-0.3%

Mar 2023-0.7%

Jun 202318%

Sep 20235.5%

Dec 20233.1%

Mar 20242.8%

Jun 20246.5%

Sep 20246.0%

Dec 20248.8%

Mar 20250.8%

Jun 20255.4%

Sep 20255.0%

Dec 20253.1%

Mar 2026-1.8%

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021-0.5%

Dec 2021-0.5%

Mar 20220.8%

Jun 20220.4%

Sep 20220.1%

Dec 2022-0.2%

Mar 20231.2%

Jun 20230.0%

Sep 2023-7.8%

Dec 2023-0.4%

Mar 20240.6%

Jun 20240.2%

Sep 2024-0.2%

Dec 20240.0%

Mar 20250.8%

Jun 20250.6%

Sep 20250.0%

Dec 2025-1.6%

Mar 20261.2%

Jun 2026—

Haleon plc · HLN

Sep 20213.4%

Dec 20212.6%

Mar 20222.3%

Jun 20222.1%

Sep 20221.9%

Dec 20221.2%

Mar 20231.8%

Jun 20231.5%

Sep 20232.0%

Dec 20230.9%

Mar 20242.3%

Jun 20241.7%

Sep 20242.4%

Dec 20241.2%

Mar 20252.2%

Jun 20252.2%

Sep 20252.2%

Dec 20252.2%

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021-9.7%

Dec 2021-9.7%

Mar 2022-5.1%

Jun 2022-6.3%

Sep 2022-5.8%

Dec 2022-3.5%

Mar 2023-3.4%

Jun 2023-2.9%

Sep 2023-2.6%

Dec 2023-0.1%

Mar 20242.9%

Jun 20243.2%

Sep 20245.7%

Dec 20244.4%

Mar 202512%

Jun 20252.7%

Sep 20251.1%

Dec 20250.8%

Mar 2026-6.9%

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021-11%

Dec 2021-14%

Mar 2022-10%

Jun 2022-9.5%

Sep 202215%

Dec 20222.0%

Mar 2023-3.8%

Jun 2023-1.0%

Sep 2023-2.6%

Dec 20230.0%

Mar 2024-3.8%

Jun 20240.0%

Sep 2024-2.2%

Dec 2024-4.1%

Mar 20252.8%

Jun 20254.0%

Sep 20254.6%

Dec 20253.6%

Mar 20265.0%

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021-1.8%

Dec 2021-4.5%

Mar 20227.7%

Jun 20228.0%

Sep 202211%

Dec 2022-19%

Mar 2023-1.0%

Jun 202313%

Sep 202310%

Dec 202311%

Mar 20248.0%

Jun 20247.2%

Sep 202410%

Dec 20247.1%

Mar 20256.0%

Jun 20255.0%

Sep 20252.7%

Dec 20254.2%

Mar 20264.3%

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021-8.3%

Dec 2021-13%

Mar 2022-17%

Jun 2022-7.8%

Sep 2022-8.1%

Dec 2022-6.3%

Mar 2023-8.9%

Jun 2023-20%

Sep 2023-13%

Dec 2023-24%

Mar 2024-19%

Jun 2024-21%

Sep 2024-18%

Dec 2024-25%

Mar 2025-21%

Jun 2025-23%

Sep 20250.9%

Dec 202510%

Mar 202629%

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 20213.3%

Dec 2021-2.2%

Mar 20220.2%

Jun 20223.2%

Sep 20225.1%

Dec 20225.7%

Mar 2023-5.9%

Jun 20233.9%

Sep 20237.4%

Dec 20236.8%

Mar 20244.2%

Jun 20245.9%

Sep 20247.0%

Dec 20244.9%

Mar 20250.8%

Jun 20254.7%

Sep 20257.1%

Dec 20255.9%

Mar 20265.3%

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 20211.7%

Dec 20210.2%

Mar 2022-2.0%

Jun 2022-2.7%

Sep 20221.2%

Dec 2022-2.8%

Mar 20230.0%

Jun 2023-2.0%

Sep 20231.1%

Dec 20232.4%

Mar 2024-0.7%

Jun 20240.0%

Sep 2024-0.2%

Dec 2024-0.1%

Mar 20251.8%

Jun 20251.6%

Sep 20253.1%

Dec 20251.1%

Mar 20262.4%

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 20215.2%

Dec 20213.7%

Mar 20226.1%

Jun 20224.1%

Sep 20226.2%

Dec 20223.3%

Mar 20235.1%

Jun 20235.4%

Sep 20235.6%

Dec 20234.3%

Mar 20246.1%

Jun 20245.2%

Sep 20245.5%

Dec 20245.5%

Mar 20256.0%

Jun 20255.5%

Sep 20256.0%

Dec 20255.1%

Mar 20265.0%

Jun 2026—

Viatris Inc. · VTRS

Sep 20211.0%

Dec 2021-0.2%

Mar 20221.5%

Jun 20221.2%

Sep 20221.3%

Dec 2022-0.5%

Mar 20230.9%

Jun 20230.9%

Sep 20231.1%

Dec 2023-1.1%

Mar 20240.5%

Jun 2024-0.6%

Sep 20240.6%

Dec 2024-0.5%

Mar 2025-8.0%

Jun 20250.7%

Sep 20250.5%

Dec 2025-0.6%

Mar 2026-0.3%

Jun 2026—

Zoetis Inc. · ZTS

Sep 20216.1%

Dec 20215.0%

Mar 20227.0%

Jun 20226.4%

Sep 20226.2%

Dec 20225.8%

Mar 20236.2%

Jun 20237.3%

Sep 20236.7%

Dec 20235.8%

Mar 20246.6%

Jun 20247.1%

Sep 20247.3%

Dec 20246.6%

Mar 20257.0%

Jun 20258.2%

Sep 20257.2%

Dec 20256.7%

Mar 20266.7%

Jun 2026—

ROCE change · reported quarter history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−2.7 pp

Dec 2022−1.2 pp

Mar 2023+1.1 pp

Jun 2023+19.7 pp

Sep 2023+9.5 pp

Dec 2023+3.4 pp

Mar 2024+3.5 pp

Jun 2024−11.0 pp

Sep 2024+0.5 pp

Dec 2024+5.7 pp

Mar 2025−2.0 pp

Jun 2025−1.1 pp

Sep 2025−1.0 pp

Dec 2025−5.7 pp

Mar 2026−2.6 pp

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.6 pp

Dec 2022+0.3 pp

Mar 2023+0.4 pp

Jun 2023−0.4 pp

Sep 2023−7.9 pp

Dec 2023−0.2 pp

Mar 2024−0.6 pp

Jun 2024+0.2 pp

Sep 2024+7.6 pp

Dec 2024+0.4 pp

Mar 2025+0.2 pp

Jun 2025+0.4 pp

Sep 2025+0.2 pp

Dec 2025−1.6 pp

Mar 2026+0.4 pp

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−1.5 pp

Dec 2022−1.4 pp

Mar 2023−0.5 pp

Jun 2023−0.6 pp

Sep 2023+0.1 pp

Dec 2023−0.3 pp

Mar 2024+0.5 pp

Jun 2024+0.2 pp

Sep 2024+0.4 pp

Dec 2024+0.3 pp

Mar 2025−0.1 pp

Jun 2025+0.5 pp

Sep 2025−0.2 pp

Dec 2025+1.0 pp

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+3.9 pp

Dec 2022+6.2 pp

Mar 2023+1.7 pp

Jun 2023+3.4 pp

Sep 2023+3.2 pp

Dec 2023+3.4 pp

Mar 2024+6.3 pp

Jun 2024+6.1 pp

Sep 2024+8.3 pp

Dec 2024+4.5 pp

Mar 2025+9.1 pp

Jun 2025−0.5 pp

Sep 2025−4.6 pp

Dec 2025−3.6 pp

Mar 2026−18.9 pp

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+25.5 pp

Dec 2022+16.3 pp

Mar 2023+6.4 pp

Jun 2023+8.5 pp

Sep 2023−17.5 pp

Dec 2023−2.0 pp

Mar 20240.0 pp

Jun 2024+1.0 pp

Sep 2024+0.4 pp

Dec 2024−4.1 pp

Mar 2025+6.6 pp

Jun 2025+4.0 pp

Sep 2025+6.8 pp

Dec 2025+7.7 pp

Mar 2026+2.2 pp

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+12.3 pp

Dec 2022−14.1 pp

Mar 2023−8.7 pp

Jun 2023+4.5 pp

Sep 2023−0.3 pp

Dec 2023+29.4 pp

Mar 2024+9.0 pp

Jun 2024−5.3 pp

Sep 20240.0 pp

Dec 2024−3.7 pp

Mar 2025−2.0 pp

Jun 2025−2.2 pp

Sep 2025−7.5 pp

Dec 2025−2.9 pp

Mar 2026−1.7 pp

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.2 pp

Dec 2022+6.7 pp

Mar 2023+8.5 pp

Jun 2023−11.7 pp

Sep 2023−5.2 pp

Dec 2023−17.7 pp

Mar 2024−10.5 pp

Jun 2024−1.8 pp

Sep 2024−5.0 pp

Dec 2024−1.0 pp

Mar 2025−1.3 pp

Jun 2025−1.3 pp

Sep 2025+19.2 pp

Dec 2025+35.4 pp

Mar 2026+50.1 pp

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+1.8 pp

Dec 2022+7.9 pp

Mar 2023−6.1 pp

Jun 2023+0.7 pp

Sep 2023+2.3 pp

Dec 2023+1.1 pp

Mar 2024+10.1 pp

Jun 2024+2.0 pp

Sep 2024−0.4 pp

Dec 2024−1.9 pp

Mar 2025−3.4 pp

Jun 2025−1.2 pp

Sep 2025+0.1 pp

Dec 2025+1.0 pp

Mar 2026+4.5 pp

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−0.5 pp

Dec 2022−3.0 pp

Mar 2023+2.0 pp

Jun 2023+0.7 pp

Sep 2023−0.1 pp

Dec 2023+5.2 pp

Mar 2024−0.7 pp

Jun 2024+2.0 pp

Sep 2024−1.3 pp

Dec 2024−2.5 pp

Mar 2025+2.5 pp

Jun 2025+1.6 pp

Sep 2025+3.3 pp

Dec 2025+1.2 pp

Mar 2026+0.6 pp

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+1.0 pp

Dec 2022−0.4 pp

Mar 2023−1.0 pp

Jun 2023+1.3 pp

Sep 2023−0.6 pp

Dec 2023+1.0 pp

Mar 2024+1.0 pp

Jun 2024−0.2 pp

Sep 2024−0.1 pp

Dec 2024+1.2 pp

Mar 2025−0.1 pp

Jun 2025+0.3 pp

Sep 2025+0.5 pp

Dec 2025−0.4 pp

Mar 2026−1.0 pp

Jun 2026—

Viatris Inc. · VTRS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.3 pp

Dec 2022−0.3 pp

Mar 2023−0.6 pp

Jun 2023−0.3 pp

Sep 2023−0.2 pp

Dec 2023−0.6 pp

Mar 2024−0.4 pp

Jun 2024−1.5 pp

Sep 2024−0.5 pp

Dec 2024+0.6 pp

Mar 2025−8.5 pp

Jun 2025+1.3 pp

Sep 2025−0.1 pp

Dec 2025−0.1 pp

Mar 2026+7.7 pp

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+0.1 pp

Dec 2022+0.8 pp

Mar 2023−0.8 pp

Jun 2023+0.9 pp

Sep 2023+0.5 pp

Dec 20230.0 pp

Mar 2024+0.4 pp

Jun 2024−0.2 pp

Sep 2024+0.6 pp

Dec 2024+0.8 pp

Mar 2025+0.4 pp

Jun 2025+1.1 pp

Sep 2025−0.1 pp

Dec 2025+0.1 pp

Mar 2026−0.3 pp

Jun 2026—

07 · compare level, then change

Valuation Against Growth & Quality

Alkermes plc has the lowest Guarded PEG among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 0.58×. Neurocrine Biosciences, Inc. is next at 0.73×. Trulieve Cannabis Corp. has the lowest P/E at -13.3×, so level and change sit with different companies. 7 of 28 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Alkermes plc has the lowest comparable Guarded PEG at 0.58×, 20.5% below Neurocrine Biosciences, Inc.. Only 7 of 28 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderAlkermes plc · 0.58×

Gap20.5% versus #2 · Neurocrine Biosciences, Inc.

Persistence0/8 recent comparable periods

Coverage7/28 companies · 38 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.

Guarded PEGlowest PEG

1Alkermes plc ALKS0.6

2Neurocrine Biosciences, Inc. NBIX0.7

3Lantheus Holdings, Inc. LNTH1.0

4Haleon plc HLN · older report1.0

5Phibro Animal Health Corporation PAHC1.3

P/Elowest P/E

1Trulieve Cannabis Corp. TRLV-13.3

2Indivior Pharmaceuticals, Inc. INDV3.1

3HUTCHMED (China) Limited HCM · older report5.1

4BioCryst Pharmaceuticals, Inc. BCRX6.5

5Prestige Consumer Healthcare Inc. PBH15.2

Valuation · company comparison

7/28 level · 25/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Guarded PEG	P/E	Reported
Hims & Hers Health, Inc. HIMS	4.6	63.7	Mar 2026
United Therapeutics Corporation UTHR	2.7	21.9	Mar 2026
Zoetis Inc. ZTS	2.0	19.6	Mar 2026
Phibro Animal Health Corporation PAHC	1.3	23.7	Mar 2026
Haleon plc HLN	1.0	20.1	Dec 2025
Lantheus Holdings, Inc. LNTH	1.0	18.3	Mar 2026
Neurocrine Biosciences, Inc. NBIX	0.7	20.3	Mar 2026
Alkermes plc ALKS	0.6	39.3	Mar 2026
Teva Pharmaceutical Industries Limited TEVA	—	22.7	Mar 2026
Viatris Inc. VTRS	—	216.6	Mar 2026
Elanco Animal Health Incorporated ELAN	—	335.7	Mar 2026
Liquidia Corporation LQDA	—	269.6	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	—	53.5	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	—	32.7	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	—	3.1	Mar 2026
Supernus Pharmaceuticals, Inc. SUPN	—	27.4	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	—	6.5	Mar 2026
Prestige Consumer Healthcare Inc. PBH	—	15.2	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	—	21.0	Mar 2026
HUTCHMED (China) Limited HCM	—	5.1	Dec 2025
ANI Pharmaceuticals, Inc. ANIP	—	19.5	Mar 2026
Bausch Health Companies Inc. BHC	—	16.6	Mar 2026
Trulieve Cannabis Corp. TRLV	—	-13.3	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	—	96.7	Mar 2026
Eton Pharmaceuticals, Inc. ETON	—	93.8	Mar 2026

Full 20-quarter history · every available company

Guarded PEG · reported quarter history

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 20240.3

Dec 2024—

Mar 2025—

Jun 20250.6

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 20240.7

Mar 20250.7

Jun 20250.6

Sep 20250.9

Dec 20251.0

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 20254.6

Dec 2025—

Mar 2026—

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 20261.0

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20230.9

Mar 2024—

Jun 2024—

Sep 2024—

Dec 20241.2

Mar 2025—

Jun 2025—

Sep 20252.8

Dec 20250.7

Mar 2026—

Jun 2026—

Phibro Animal Health Corporation · PAHC

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 20241.3

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20230.4

Sep 20230.5

Dec 20230.4

Mar 20240.3

Jun 20240.6

Sep 20240.6

Dec 20240.6

Mar 20250.7

Jun 20250.6

Sep 20251.0

Dec 20251.3

Mar 20262.7

Jun 2026—

Zoetis Inc. · ZTS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20234.6

Sep 20232.9

Dec 20233.1

Mar 20241.9

Jun 20244.6

Sep 20244.5

Dec 20243.8

Mar 20255.0

Jun 20252.2

Sep 20252.4

Dec 20252.4

Mar 20262.0

Jun 2026—

P/E · reported quarter history

Showing the 12 largest of 25 companies with a series here. The remaining 13 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 202354.9

Sep 202322.6

Dec 202313.2

Mar 202410.7

Jun 202414.4

Sep 202414.4

Dec 202413.3

Mar 202515.8

Jun 202513.8

Sep 202514.9

Dec 202519.6

Mar 202639.3

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 202436.7

Dec 202417.8

Mar 202514.2

Jun 202516.6

Sep 2025335.7

Dec 2025—

Mar 2026—

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202210.9

Dec 202228.7

Mar 202318.3

Jun 202324.8

Sep 202325.2

Dec 202328.4

Mar 202428.3

Jun 202427.6

Sep 202429.9

Dec 202424.1

Mar 202525.3

Jun 202522.5

Sep 202520.2

Dec 202520.1

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024252.4

Sep 202441.9

Dec 202445.6

Mar 202542.8

Jun 202562.3

Sep 2025105.0

Dec 202563.7

Mar 2026—

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 20226.4

Dec 20225.8

Mar 20233.9

Jun 20234.3

Sep 2023—

Dec 202387.7

Mar 2024179.4

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025691.8

Sep 202586.3

Dec 202555.0

Mar 202653.5

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022153.6

Sep 202247.2

Dec 2022127.4

Mar 2023—

Jun 2023204.7

Sep 202348.6

Dec 202313.3

Mar 20249.5

Jun 202413.2

Sep 202418.3

Dec 202420.5

Mar 202527.7

Jun 202521.8

Sep 202521.6

Dec 202519.5

Mar 202618.3

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026269.6

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 202121.0

Dec 202192.6

Mar 2022130.2

Jun 2022886.2

Sep 2022186.3

Dec 202276.6

Mar 2023168.7

Jun 202354.5

Sep 202360.5

Dec 202353.3

Mar 202438.0

Jun 202441.6

Sep 202430.9

Dec 202441.5

Mar 202537.5

Jun 202537.2

Sep 202533.6

Dec 202530.4

Mar 202620.3

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 202114.8

Dec 202121.1

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 202533.7

Dec 202525.8

Mar 202622.7

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 202118.7

Dec 202121.5

Mar 202212.4

Jun 202217.8

Sep 202214.2

Dec 202218.5

Mar 202315.1

Jun 202312.5

Sep 202312.4

Dec 202311.1

Mar 202410.9

Jun 202414.6

Sep 202415.7

Dec 202414.3

Mar 202512.3

Jun 202511.2

Sep 202515.9

Dec 202517.5

Mar 202621.9

Jun 2026—

Viatris Inc. · VTRS

Sep 2021—

Dec 2021—

Mar 202215.8

Jun 20228.9

Sep 20227.0

Dec 20226.5

Mar 202317.2

Jun 202319.2

Sep 202319.7

Dec 2023216.6

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

Zoetis Inc. · ZTS

Sep 202146.8

Dec 202157.2

Mar 202243.3

Jun 202239.0

Sep 202233.9

Dec 202232.6

Mar 202337.6

Jun 202336.2

Sep 202335.4

Dec 202338.9

Mar 202432.6

Jun 202433.9

Sep 202436.7

Dec 202429.8

Mar 202529.9

Jun 202527.2

Sep 202524.9

Dec 202520.9

Mar 202619.6

Jun 2026—

08 · compare level, then change

Enterprise Value & Book Value

Amylyx Pharmaceuticals, Inc. has the lowest EV/EBITDA among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 0.04×. BioCryst Pharmaceuticals, Inc. is next at 2.8×. Perrigo Company plc has the lowest P/BV at 0.53×, so level and change sit with different companies. 27 of 28 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Amylyx Pharmaceuticals, Inc. leads ev/ebitda at 0.04×; Perrigo Company plc leads p/bv at 0.53×.

LeaderAmylyx Pharmaceuticals, Inc. · 0.04×

Gap98.6% versus #2 · BioCryst Pharmaceuticals, Inc.

Persistence0/8 recent comparable periods

Coverage27/28 companies · 368 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.

EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.

EV/EBITDAlowest EV/EBITDA

1Amylyx Pharmaceuticals, Inc. AMLX0.0

2BioCryst Pharmaceuticals, Inc. BCRX2.8

3Indivior Pharmaceuticals, Inc. INDV3.1

4Trulieve Cannabis Corp. TRLV4.3

5Bausch Health Companies Inc. BHC6.9

P/BVlowest P/BV

1Perrigo Company plc PRGO0.5

2Trulieve Cannabis Corp. TRLV0.9

3Viatris Inc. VTRS1.0

4Prestige Consumer Healthcare Inc. PBH1.5

5Elanco Animal Health Incorporated ELAN1.8

Enterprise and book valuation · company comparison

27/28 level · 24/28 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	EV/EBITDA	P/BV	Reported
Hims & Hers Health, Inc. HIMS	137.6	10.7	Mar 2026
Eton Pharmaceuticals, Inc. ETON	110.7	22.1	Mar 2026
HUTCHMED (China) Limited HCM	86.1	1.9	Dec 2025
Supernus Pharmaceuticals, Inc. SUPN	71.6	2.8	Mar 2026
Liquidia Corporation LQDA	69.9	30.7	Mar 2026
Harrow, Inc. HROW	37.8	45.8	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSA	34.1	6.1	Mar 2026
Alkermes plc ALKS	30.1	3.4	Mar 2026
Xeris Biopharma Holdings, Inc. XERS	23.9	76.9	Mar 2026
Elanco Animal Health Incorporated ELAN	21.2	1.8	Mar 2026
ANI Pharmaceuticals, Inc. ANIP	16.5	3.1	Mar 2026
Neurocrine Biosciences, Inc. NBIX	15.1	3.9	Mar 2026
United Therapeutics Corporation UTHR	15.0	4.2	Mar 2026
Haleon plc HLN	14.7	2.0	Dec 2025
Teva Pharmaceutical Industries Limited TEVA	14.7	4.3	Mar 2026
Zoetis Inc. ZTS	14.3	15.4	Mar 2026
Lantheus Holdings, Inc. LNTH	13.6	4.1	Mar 2026
Phibro Animal Health Corporation PAHC	12.6	6.2	Mar 2026
Prestige Consumer Healthcare Inc. PBH	11.1	1.5	Mar 2026
Amneal Pharmaceuticals, Inc. AMRX	10.1	-86.5	Mar 2026
Perrigo Company plc PRGO	10.1	0.5	Mar 2026
Viatris Inc. VTRS	9.6	1.0	Mar 2026
Bausch Health Companies Inc. BHC	6.9	-1.0	Mar 2026
Trulieve Cannabis Corp. TRLV	4.3	0.9	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	3.1	-5.3	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	2.8	-4.4	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLX	0.0	5.7	Mar 2026
Regencell Bioscience Holdings Limited RGC	—	8,516.0	Dec 2025

Full 20-quarter history · every available company

EV/EBITDA · reported quarter history

Showing the 12 largest of 27 companies with a series here. The remaining 15 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 2021313.9

Dec 202120.7

Mar 202283.3

Jun 2022386.0

Sep 2022—

Dec 202256.7

Mar 2023—

Jun 202317.0

Sep 20239.7

Dec 20238.7

Mar 20247.9

Jun 202410.0

Sep 202411.3

Dec 20248.9

Mar 202511.1

Jun 20259.4

Sep 202510.1

Dec 202514.6

Mar 202630.1

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 202188.5

Dec 202150.2

Mar 202236.3

Jun 202220.3

Sep 202213.9

Dec 202213.3

Mar 202311.6

Jun 202312.7

Sep 202313.1

Dec 2023—

Mar 202418.8

Jun 202416.7

Sep 202416.0

Dec 202413.2

Mar 202512.0

Jun 202513.3

Sep 202516.1

Dec 202521.8

Mar 202621.2

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 202218.8

Dec 202219.1

Mar 202317.5

Jun 202316.9

Sep 202316.8

Dec 202316.6

Mar 202416.8

Jun 202416.5

Sep 202418.0

Dec 202416.7

Mar 202517.6

Jun 202516.0

Sep 202514.8

Dec 202514.7

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20241,479.7

Jun 2024176.0

Sep 202466.6

Dec 202463.9

Mar 202548.0

Jun 202571.4

Sep 202585.0

Dec 202549.5

Mar 2026137.6

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 202270.6

Mar 202323.5

Jun 202320.2

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025292.9

Sep 202565.2

Dec 202534.8

Mar 202634.1

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 202133.7

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022367.9

Dec 202242.6

Mar 2023306.5

Jun 202370.7

Sep 202341.9

Dec 20239.9

Mar 20247.7

Jun 202410.4

Sep 202413.5

Dec 202411.1

Mar 202512.4

Jun 202511.5

Sep 20259.4

Dec 202511.8

Mar 202613.6

Jun 2026—

Liquidia Corporation · LQDA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 202669.9

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 202139.7

Dec 202168.9

Mar 2022102.2

Jun 2022113.2

Sep 202278.3

Dec 202240.8

Mar 202362.6

Jun 202350.2

Sep 202345.6

Dec 202345.6

Mar 202426.8

Jun 202423.4

Sep 202417.7

Dec 202421.7

Mar 202520.0

Jun 202522.7

Sep 202523.0

Dec 202520.2

Mar 202615.1

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 20219.8

Dec 202110.2

Mar 202217.6

Jun 202226.6

Sep 202232.4

Dec 2022—

Mar 2023—

Jun 2023914.8

Sep 2023—

Dec 202318.4

Mar 202424.6

Jun 202418.0

Sep 202423.9

Dec 202453.1

Mar 202522.4

Jun 202518.1

Sep 202513.4

Dec 202515.7

Mar 202614.7

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 202114.2

Dec 202114.2

Mar 20226.9

Jun 20229.9

Sep 20227.5

Dec 202210.4

Mar 20238.2

Jun 20237.4

Sep 20237.4

Dec 20236.5

Mar 20246.1

Jun 20248.8

Sep 20249.7

Dec 20248.9

Mar 20257.3

Jun 20256.5

Sep 20259.7

Dec 202511.6

Mar 202615.0

Jun 2026—

Viatris Inc. · VTRS

Sep 202110.1

Dec 20218.7

Mar 20227.2

Jun 20226.9

Sep 20226.4

Dec 20226.8

Mar 20236.9

Jun 20237.3

Sep 20237.3

Dec 20238.6

Mar 20249.5

Jun 202410.5

Sep 202411.0

Dec 20249.7

Mar 2025—

Jun 2025156.1

Sep 2025195.6

Dec 2025202.8

Mar 20269.6

Jun 2026—

Zoetis Inc. · ZTS

Sep 202130.6

Dec 202137.0

Mar 202228.4

Jun 202225.8

Sep 202222.4

Dec 202221.4

Mar 202324.7

Jun 202324.7

Sep 202324.4

Dec 202327.1

Mar 202422.8

Jun 202423.0

Sep 202424.7

Dec 202420.3

Mar 202520.4

Jun 202519.0

Sep 202517.6

Dec 202515.0

Mar 202614.3

Jun 2026—

P/BV · reported quarter history

Showing the 12 largest of 28 companies with a series here. The remaining 16 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Alkermes plc · ALKS

Sep 20214.6

Dec 20213.4

Mar 20224.0

Jun 20224.5

Sep 20223.5

Dec 20224.1

Mar 20234.7

Jun 20234.1

Sep 20233.4

Dec 20233.9

Mar 20243.7

Jun 20243.1

Sep 20243.5

Dec 20243.2

Mar 20253.6

Jun 20252.9

Sep 20252.9

Dec 20252.6

Mar 20263.4

Jun 2026—

Elanco Animal Health Incorporated · ELAN

Sep 20212.0

Dec 20211.8

Mar 20221.6

Jun 20221.3

Sep 20220.9

Dec 20220.8

Mar 20230.6

Jun 20230.7

Sep 20230.9

Dec 20231.2

Mar 20241.3

Jun 20241.2

Sep 20241.1

Dec 20241.0

Mar 20250.8

Jun 20251.1

Sep 20251.5

Dec 20251.7

Mar 20261.8

Jun 2026—

Haleon plc · HLN

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 20221.5

Dec 20221.9

Mar 20231.9

Jun 20231.9

Sep 20231.9

Dec 20231.8

Mar 20241.9

Jun 20241.8

Sep 20242.2

Dec 20242.1

Mar 20252.3

Jun 20252.1

Sep 20251.8

Dec 20252.0

Mar 2026—

Jun 2026—

Hims & Hers Health, Inc. · HIMS

Sep 20214.3

Dec 20214.0

Mar 20223.4

Jun 20222.9

Sep 20223.7

Dec 20224.3

Mar 20236.6

Jun 20236.2

Sep 20234.1

Dec 20235.5

Mar 20249.6

Jun 202412.1

Sep 20249.1

Dec 202411.2

Mar 202512.0

Jun 202519.8

Sep 202522.2

Dec 202513.6

Mar 202610.7

Jun 2026—

Kiniksa Pharmaceuticals International, plc · KNSA

Sep 20213.7

Dec 20214.4

Mar 20224.1

Jun 20224.4

Sep 20222.3

Dec 20222.6

Mar 20231.9

Jun 20232.4

Sep 20233.0

Dec 20232.8

Mar 20243.2

Jun 20243.1

Sep 20244.1

Dec 20243.3

Mar 20253.5

Jun 20254.1

Sep 20255.5

Dec 20255.5

Mar 20266.1

Jun 2026—

Lantheus Holdings, Inc. · LNTH

Sep 20213.5

Dec 20214.2

Mar 20227.4

Jun 20228.0

Sep 20227.6

Dec 20227.7

Mar 202312.7

Jun 202310.4

Sep 20236.8

Dec 20235.2

Mar 20244.6

Jun 20245.4

Sep 20246.5

Dec 20245.6

Mar 20255.8

Jun 20255.0

Sep 20253.3

Dec 20253.9

Mar 20264.1

Jun 2026—

Liquidia Corporation · LQDA

Sep 20212.0

Dec 20213.9

Mar 20226.9

Jun 20222.8

Sep 20223.7

Dec 20224.6

Mar 20235.5

Jun 20238.4

Sep 20238.6

Dec 202317.5

Mar 202413.0

Jun 202414.6

Sep 20247.7

Dec 202412.6

Mar 202525.3

Jun 202570.4

Sep 202589.5

Dec 202567.2

Mar 202630.7

Jun 2026—

Neurocrine Biosciences, Inc. · NBIX

Sep 20216.8

Dec 20215.9

Mar 20226.4

Jun 20226.6

Sep 20226.6

Dec 20226.8

Mar 20235.9

Jun 20235.0

Sep 20235.5

Dec 20235.8

Mar 20245.8

Jun 20245.5

Sep 20244.3

Dec 20245.2

Mar 20254.3

Jun 20254.6

Sep 20254.7

Dec 20254.4

Mar 20263.9

Jun 2026—

Teva Pharmaceutical Industries Limited · TEVA

Sep 20211.0

Dec 20210.9

Mar 20221.1

Jun 20220.9

Sep 20221.0

Dec 20221.3

Mar 20231.3

Jun 20231.2

Sep 20231.7

Dec 20231.6

Mar 20242.2

Jun 20242.9

Sep 20243.4

Dec 20244.7

Mar 20252.8

Jun 20252.8

Sep 20253.2

Dec 20254.5

Mar 20264.3

Jun 2026—

United Therapeutics Corporation · UTHR

Sep 20212.2

Dec 20212.5

Mar 20222.0

Jun 20222.5

Sep 20222.1

Dec 20222.7

Mar 20232.0

Jun 20231.9

Sep 20231.9

Dec 20231.7

Mar 20241.9

Jun 20242.5

Sep 20242.6

Dec 20242.5

Mar 20252.0

Jun 20251.8

Sep 20252.7

Dec 20253.0

Mar 20264.2

Jun 2026—

Viatris Inc. · VTRS

Sep 20210.8

Dec 20210.8

Mar 20220.7

Jun 20220.6

Sep 20220.5

Dec 20220.6

Mar 20230.5

Jun 20230.6

Sep 20230.6

Dec 20230.6

Mar 20240.7

Jun 20240.6

Sep 20240.7

Dec 20240.8

Mar 20250.6

Jun 20250.6

Sep 20250.7

Dec 20250.9

Mar 20261.0

Jun 2026—

Zoetis Inc. · ZTS

Sep 202119.6

Dec 202125.4

Mar 202219.1

Jun 202217.6

Sep 202214.8

Dec 202215.4

Mar 202317.1

Jun 202317.2

Sep 202315.7

Dec 202318.1

Mar 202415.3

Jun 202415.8

Sep 202416.9

Dec 202415.3

Mar 202515.8

Jun 202513.9

Sep 202512.0

Dec 202516.1

Mar 202615.4

Jun 2026—

09 · let price answer last

Market action

Liquidia Corporation has the strongest one-year price move in Drug Manufacturers - Specialty & Generic at +391.1%. It also leads on Mansfield relative strength against the S&P 500 at +98.8%. 16 of 28 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-07-28.

Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.

Price and relative strength

Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.

Before the conclusion · check the blind spots

What can make this comparison misleading?

This Drug Manufacturers - Specialty & Generic comparison names 5 specific ways its own evidence can mislead, all listed below. 3 of the 28 companies report on an older date than the sector's freshest reporters, so their ranks are marked stale. A high growth rate can still be a low-base artefact.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
3 companies have older fundamental reporting dates than the sector’s freshest reporters; their ranks carry a stale marker.

10 · the complete set

Which companies are included?

All 28 companies in the canonical Drug Manufacturers - Specialty & Generic membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.

AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.

Company	Market value	Price	Priced to	Latest fundamentals
Haleon plc HLN	$44.6B	$10.3	2026-07-28	Dec 2025
Teva Pharmaceutical Industries Limited TEVA	$36.9B	$31.7	2026-07-28	Mar 2026
Zoetis Inc. ZTS	$32.5B	$77.5	2026-07-28	Mar 2026
United Therapeutics Corporation UTHR	$22.2B	$524	2026-07-28	Mar 2026
Viatris Inc. VTRSAHEAD23/26 WEEKS	$20.8B	$17.9	2026-07-28	Mar 2026
Neurocrine Biosciences, Inc. NBIXAHEAD	$18.4B	$183	2026-07-28	Mar 2026
Elanco Animal Health Incorporated ELANAHEAD	$12.7B	$25.5	2026-07-28	Mar 2026
Alkermes plc ALKSAHEAD22/26 WEEKS	$8.5B	$50.5	2026-07-28	Mar 2026
Liquidia Corporation LQDAAHEAD22/26 WEEKS	$7.7B	$86.8	2026-07-28	Mar 2026
Hims & Hers Health, Inc. HIMSAHEAD	$6.8B	$29.3	2026-07-28	Mar 2026
Lantheus Holdings, Inc. LNTHAHEAD26/26 WEEKS	$6.7B	$103	2026-07-28	Mar 2026
Kiniksa Pharmaceuticals International, plc KNSAAHEAD23/26 WEEKS	$6.1B	$79.4	2026-07-28	Mar 2026
Amneal Pharmaceuticals, Inc. AMRXAHEAD	$6.0B	$18.8	2026-07-28	Mar 2026
Indivior Pharmaceuticals, Inc. INDV	$5.0B	$41.0	2026-07-28	Mar 2026
Regencell Bioscience Holdings Limited RGC	$3.0B	$6.0	2026-07-28	Dec 2025
Supernus Pharmaceuticals, Inc. SUPN	$2.8B	$47.7	2026-07-28	Mar 2026
BioCryst Pharmaceuticals, Inc. BCRX	$2.5B	$9.7	2026-07-28	Mar 2026
Prestige Consumer Healthcare Inc. PBH	$2.5B	$51.7	2026-07-28	Mar 2026
Amylyx Pharmaceuticals, Inc. AMLXAHEAD	$2.2B	$19.6	2026-07-28	Mar 2026
HUTCHMED (China) Limited HCMLAGGING, FUNDAMENTALS UP	$2.0B	$11.2	2026-07-28	Dec 2025
ANI Pharmaceuticals, Inc. ANIP	$1.7B	$81.0	2026-07-28	Mar 2026
Bausch Health Companies Inc. BHC	$1.7B	$4.5	2026-07-28	Mar 2026
Trulieve Cannabis Corp. TRLV	$1.6B	$8.3	2026-07-28	Mar 2026
Xeris Biopharma Holdings, Inc. XERSAHEAD	$1.5B	$8.2	2026-07-28	Mar 2026
Phibro Animal Health Corporation PAHC	$1.5B	$36.4	2026-07-28	Mar 2026
Harrow, Inc. HROW	$1.5B	$39.3	2026-07-28	Mar 2026
Perrigo Company plc PRGO	$1.4B	$10.3	2026-07-28	Mar 2026
Eton Pharmaceuticals, Inc. ETONAHEAD24/26 WEEKS	$1.3B	$46.7	2026-07-28	Mar 2026

Evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 28 Drug Manufacturers - Specialty & Generic companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-28.

FundamentalsThrough Jun 2026 · up to 20 quarters per company

Market dataThrough 2026-07-28 · weekly price and relative-strength history

Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

Questions investors ask · short, speakable answers

Drug Manufacturers - Specialty & Generic company comparison FAQs

These 18 answers restate the Drug Manufacturers - Specialty & Generic comparison above in question form. Every one is computed from the same 28 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-28. Nothing here is estimated, and none of it is a recommendation.

Which Drug Manufacturers - Specialty & Generic company is the biggest?

Teva Pharmaceutical Industries Limited is the largest, with trailing-twelve-month revenue of $17,349 million, ahead of Viatris Inc. at $14,563 million. That covers 24 of 28 companies with comparable reporting through Mar 2026.

Which Drug Manufacturers - Specialty & Generic company is growing fastest?

Liquidia Corporation has the fastest revenue growth at 100% year on year, across 24 of 28 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.

Which Drug Manufacturers - Specialty & Generic company has the best profit margins?

Liquidia Corporation has the highest operating margin at 46.3%, from 25 of 28 comparable companies. Amylyx Pharmaceuticals, Inc. shows the biggest recent improvement, at +6111.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Drug Manufacturers - Specialty & Generic company makes the most profit?

Zoetis Inc. earns the most, at $2,643 million of trailing-twelve-month net profit, from 26 of 28 comparable companies. Amneal Pharmaceuticals, Inc. has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Drug Manufacturers - Specialty & Generic company earns the highest return on capital?

Indivior Pharmaceuticals, Inc. leads on return on capital employed at 34.8%, across 28 of 28 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Drug Manufacturers - Specialty & Generic stock is the cheapest?

On guarded PEG — where a LOWER number is cheaper — Alkermes plc screens cheapest at 0.58×. Only 7 of 28 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Which Drug Manufacturers - Specialty & Generic company has the strongest balance sheet?

United Therapeutics Corporation carries the lowest comparable gross debt at $0 million, from 26 of 28 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.

Which Drug Manufacturers - Specialty & Generic company is investing most in new capacity?

Teva Pharmaceutical Industries Limited reports the largest capital spending at $168 million, across 28 of 28 companies. Spending consumes cash before it earns anything, so treat the ranking as a diligence queue: check commissioning, utilisation and the return earned on the completed assets before reading spend as value creation.

Is the Drug Manufacturers - Specialty & Generic sector beating the market?

Drug Manufacturers - Specialty & Generic has outperformed S&P 500 by 27.8% over the last 52 weeks and 2.8% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 16 of 28 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Drug Manufacturers - Specialty & Generic stock has the strongest price momentum?

Liquidia Corporation has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Drug Manufacturers - Specialty & Generic company scores highest for research priority?

Neurocrine Biosciences, Inc. scores 76 out of 100 with 82% evidence confidence, from 28.7 points on growth and earnings, 16.4 on capital efficiency, 14.6 on valuation and 16.3 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Drug Manufacturers - Specialty & Generic companies does this comparison cover, and over what period?

It compares 28 listed companies over up to 20 reported quarters of fundamentals and 6 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Drug Manufacturers - Specialty & Generic sector?

The 28 Drug Manufacturers - Specialty & Generic companies on this page carry $261,913 million of combined market value. Haleon plc is the largest at $44,639 million, about 17% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-28.

What is the Drug Manufacturers - Specialty & Generic sector's P/E ratio?

The median price-to-earnings ratio across the 28 Drug Manufacturers - Specialty & Generic companies on this page is 22.6×, measured on the 24 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-28.

How is the Drug Manufacturers - Specialty & Generic sector performing?

16 of the 28 covered Drug Manufacturers - Specialty & Generic companies are beating S&P 500 on Mansfield relative strength. The sector itself is 27.8% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-07-28.

How many Drug Manufacturers - Specialty & Generic stocks are listed in the US?

This comparison covers 28 listed Drug Manufacturers - Specialty & Generic companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.